A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
An organoplatinum compound that possesses antineoplastic activity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Tumors or cancer of the LUNG.
Tumors or cancer of the human BREAST.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
A decrease in the number of NEUTROPHILS found in the blood.
Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).
A cell line derived from cultured tumor cells.
A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (Dictionary of Pharmacy, 1986)
The action of a drug in promoting or enhancing the effectiveness of another drug.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Simultaneous resistance to several structurally and functionally distinct drugs.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Tumors or cancer of the PERITONEUM.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Nanometer-sized particles that are nanoscale in three dimensions. They include nanocrystaline materials; NANOCAPSULES; METAL NANOPARTICLES; DENDRIMERS, and QUANTUM DOTS. The uses of nanoparticles include DRUG DELIVERY SYSTEMS and cancer targeting and imaging.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Disorders of the blood and blood forming tissues.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Water-soluble proteins found in egg whites, blood, lymph, and other tissues and fluids. They coagulate upon heating.
A subnormal level of BLOOD PLATELETS.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Inorganic compounds which contain platinum as the central atom.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
Particles consisting of aggregates of molecules held loosely together by secondary bonds. The surface of micelles are usually comprised of amphiphatic compounds that are oriented in a way that minimizes the energy of interaction between the micelle and its environment. Liquids that contain large numbers of suspended micelles are referred to as EMULSIONS.
A peptide that is a homopolymer of glutamic acid.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
Elements of limited time intervals, contributing to particular results or situations.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
The giving of drugs, chemicals, or other substances by mouth.
A malignant epithelial tumor with a glandular organization.
A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. (1/5423)

The characteristics of the adenomatous polyposis coli (APC) associated protein EB1 were examined in mammalian cells. By immunocytochemistry EB1 was shown to be closely associated with the microtubule cytoskeleton throughout the cell cycle. In interphase cells EB1 was associated with microtubules along their full length but was often particularly concentrated at their tips. During early mitosis, EB1 was localized to separating centrosomes and associated microtubules, while at metaphase it was associated with the spindle poles and associated microtubules. During cytokinesis EB1 was strongly associated with the midbody microtubules. Treatment with nocodazole caused a diffuse redistribution of EB1 immunoreactivity, whereas treatment with cytochalasin D had no effect. Interestingly, treatment with taxol abolished the EB1 association with microtubules. In nocodazole washout experiments EB1 rapidly became associated with the centrosome and repolymerizing microtubules. In taxol wash-out experiments EB1 rapidly re-associated with the microtubule cytoskeleton, resembling untreated control cells within 10 min. Immunostaining of SW480 cells, which contain truncated APC incapable of interaction with EB1, showed that the association of EB1 with microtubules throughout the cell cycle was not dependent upon an interaction with APC. These results suggest a role for EB1 in the control of microtubule dynamics in mammalian cells.  (+info)

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. (2/5423)

Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer to determine the maximum tolerated dose (MTD) of edatrexate and the toxicities associated with this combination and to report preliminary observations of efficacy with this novel combination. Thirty-six patients were enrolled in this Phase I trial. Thirty-five eligible patients were treated every 21 days in cohorts of at least three patients and were assessable for toxicity. One patient was ineligible due to hyperbilirubinemia. Stepwise dose escalations of edatrexate were administered until grade >3 nonhematological dose-limiting toxicities were reported. The initial dose level of edatrexate was 180 mg/m2; subsequent cohorts were treated with escalating doses of edatrexate (210, 240, 270, 300, 350, and 400 mg/m2). Edatrexate was administered by i.v. infusion over 1 h. Paclitaxel was administered 24 h later at a fixed dose of 175 mg/m2 as a 3-h infusion with standard dexamethasone, diphenhydramine, and cimetidine premedication. The MTD of edatrexate was reached at the 350 mg/m2 level in this study. Grade 3 diarrhea was seen in one patient at the 300 and 400 mg/m2 dose levels, requiring dose reductions. Two patients experienced grade 4 stomatitis at the 400 mg/m2 dose level and also required dose reduction, establishing the MTD as 350 mg/m2. Grade 3 nausea and vomiting were noted in two of three patients at the highest dose level. Of 35 patients, 4 patients reported grade 3 myalgias and 1 patient reported grade 3 neurosensory complaints, which were seen mostly at the 350 and 400 mg/m2 dose levels; however, 1 patient reported grade 3 myalgias at 180 mg/m2. No cumulative neurotoxicity was observed, and no patient experienced an allergic reaction to paclitaxel. In 23 patients with bidimensionally measurable disease, there were four complete (17%) and seven partial responses, with an overall response rate of 48% (95% confidence interval, 27-69%). All of the responses were seen in patients who had not received prior chemotherapy for stage IV disease. The median duration of response was not assessable because many responding patients went on to receive high-dose chemotherapy treatment with stem cell support. The combination of edatrexate and paclitaxel for treatment of metastatic breast cancer is a feasible and safe regimen. The MTD of edatrexate was 350 mg/m2 when combined with a 3-h infusion of paclitaxel (175 mg/m2) given 24 h later. Activity was noted even among patients who had relapsed shortly after receiving methotrexate- and/or doxorubicin-containing adjuvant regimens. Additional studies evaluating the sequences and dosing schema for this combination are warranted to improve the response proportion and define the duration of the response.  (+info)

A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. (3/5423)

A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics of the anthrapyrazole losoxantrone in combination with paclitaxel in adult patients with advanced solid malignancies. Losoxantrone was administered as a 10-min infusion in combination with paclitaxel on either a 24- or 3-h schedule. The starting dose level was 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel (as a 24- or 3-h i.v. infusion) without granulocyte colony-stimulating factor (G-CSF). Administration of these agents at the starting dose level and dose escalation was feasible only with G-CSF support. The following dose levels (losoxantrone/paclitaxel, in mg/m2) of losoxantrone and paclitaxel as a 3-h infusion were also evaluated: 50/135, 50/175, 50/200, 50/225, and 60/225. The sequence-dependent toxicological and pharmacological effects of losoxantrone and paclitaxel on the 24- and 3-h schedules of paclitaxel were also assessed. The MTD was defined as the dose at which >50% of the patients experienced DLT during the first two courses of therapy. DLTs, mainly myelosuppression, occurring during the first course of therapy were noted in four of six and five of eight patients treated with 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel over 24 and 3 h, respectively, without G-CSF. DLTs during the first two courses of therapy were observed in one of six patients at the 50/175 (losoxantrone/paclitaxel) mg/m2 dose level, two of four patients at the 50/200 mg/m2 dose level, one of four patients at the 50/225 mg/m2 dose level, and two of five patients at the 60/225 mg/m2 dose level. The degree of thrombocytopenia was worse, albeit not statistically significant, when 24-h paclitaxel preceded losoxantrone, with a mean percentage decrement in platelet count during course 1 of 80.7%, compared to 43.8% with the reverse sequence (P = 0.19). Losoxantrone clearance was not significantly altered by the sequence or schedule of paclitaxel. Cardiac toxicity was observed; however, it was not related to total cumulative dose of losoxantrone. An unacceptably high rate of DLTs at the first dose level of 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel administered as either a 24- or 3-h i.v. infusion precluded dose escalation without G-CSF support. The addition of G-CSF to the regimen permitted further dose escalation without reaching the MTD. Losoxantrone at 50 mg/m2 followed by paclitaxel (3-h i.v. infusion) at 175 mg/m2 with G-CSF support is recommended for further clinical trials.  (+info)

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. (4/5423)

Overexpression of the HER-2/neu proto-oncogene, which encodes the tyrosine kinase receptor p185neu, has been observed in tumors from breast cancer patients. We demonstrated previously that emodin, a tyrosine kinase inhibitor, suppresses tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses transformation phenotypes of these cells in vitro. In the present study, we examined whether emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and whether emodin can sensitize these tumors to paclitaxel, a commonly used chemotherapeutic agent for breast cancer patients. We found that emodin significantly inhibited tumor growth and prolonged survival in mice bearing HER-2/neu-overexpressing human breast cancer cells. Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Both immunohistochemical staining and Western blot analysis showed that emodin decreases tyrosine phosphorylation of HER-2/neu in tumor tissue. Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. The results may have important implications in chemotherapy for HER-2/neu-overexpressing breast tumors.  (+info)

Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. (5/5423)

Adenovirus (Ad) enters target cells by receptor-mediated endocytosis, escapes to the cytosol, and then delivers its DNA genome into the nucleus. Here we analyzed the trafficking of fluorophore-tagged viruses in HeLa and TC7 cells by time-lapse microscopy. Our results show that native or taxol-stabilized microtubules (MTs) support alternating minus- and plus end-directed movements of cytosolic virus with elementary speeds up to 2.6 micrometer/s. No directed movement was observed in nocodazole-treated cells. Switching between plus- and minus end-directed elementary speeds at frequencies up to 1 Hz was observed in the periphery and near the MT organizing center (MTOC) after recovery from nocodazole treatment. MT-dependent motilities allowed virus accumulation near the MTOC at population speeds of 1-10 micrometer/min, depending on the cell type. Overexpression of p50/dynamitin, which is known to affect dynein-dependent minus end-directed vesicular transport, significantly reduced the extent and the frequency of minus end-directed migration of cytosolic virus, and increased the frequency, but not the extent of plus end-directed motility. The data imply that a single cytosolic Ad particle engages with two types of MT-dependent motor activities, the minus end- directed cytoplasmic dynein and an unknown plus end- directed activity.  (+info)

CLIP-170 highlights growing microtubule ends in vivo. (6/5423)

A chimera with the green fluorescent protein (GFP) has been constructed to visualize the dynamic properties of the endosome-microtubule linker protein CLIP170 (GFP-CLIP170). GFP-CLIP170 binds in stretches along a subset of microtubule ends. These fluorescent stretches appear to move with the growing tips of microtubules at 0.15-0.4 microm/s, comparable to microtubule elongation in vivo. Analysis of speckles along dynamic GFP-CLIP170 stretches suggests that CLIP170 treadmills on growing microtubule ends, rather than being continuously transported toward these ends. Drugs affecting microtubule dynamics rapidly inhibit movement of GFP-CLIP170 dashes. We propose that GFP-CLIP170 highlights growing microtubule ends by specifically recognizing the structure of a segment of newly polymerized tubulin.  (+info)

A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. (7/5423)

Clinically available taxanes represent one of the most promising class of antitumor agents, despite several problems with their solubility and toxicity. In an attempt to improve the pharmacological profile of taxanes, a new series of analogues was synthesized from 14beta-hydroxy-10-deacetylbaccatin III and tested in a panel of human tumor cell lines. On the basis of the pattern of cytotoxicity and lack of cross-resistance in tumor cell lines expressing the typical multidrug-resistant phenotype, a compound (IDN5109) was selected for preclinical development. A comparative efficacy study of IDN5109 and paclitaxel was performed using a large panel of human tumor xenografts, characterized by intrinsic (seven tumors) or acquired (four tumors) resistance to cisplatin or doxorubicin, including four ovarian, one breast, one cervical, three lung, one colon, and one prostatic carcinoma. Drugs were delivered i.v. according to the same schedule (four times every 4th day). IDN5109 achieved a very high level of activity (percentage tumor weight inhibition >70%; log10 cell kill >1) in all but one of the tested tumors. Compared to paclitaxel, IDN5109 exhibited a significantly superior activity in six tumors (including the four tumors that were resistant to paclitaxel) and a comparable activity against the other five paclitaxel-responsive tumors. Additional advantages of IDN5109 over paclitaxel were also suggested by its toxicity profile. IDN5109 was not only less toxic (maximal tolerated doses were 90 and 54 mg/kg for IDN5109 and paclitaxel, respectively), but it also appeared to be endowed with a reduced neurotoxic potential and an improved profile of tolerability compared to the parent drug. Furthermore, the best antitumor efficacy was often already reached with doses lower than the maximal tolerated dose, suggesting an improved therapeutic index for the new drug. In conclusion, the results support the preclinical interest of IDN5109 in terms of the toxicity profile and of the efficacy with particular reference to the ability to overcome multiple mechanisms of drug resistance.  (+info)

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. (8/5423)

PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as first-line chemotherapy in women with incompletely resected stage III and stage IV ovarian carcinoma. PATIENTS AND METHODS: Starting doses were paclitaxel 110 mg/m2 administered over 24 hours (day 1), followed by cisplatin 50 mg/m2 over 3 hours (day 2) and topotecan 0.3 mg/m2/d over 30 minutes for 5 consecutive days (days 2 to 6). Treatment was repeated every 3 weeks. After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6. RESULTS: Twenty-one patients received a total of 116 courses at four different dose levels. The DLT was neutropenia. At the first dose level, all six patients experienced grade 4 myelosuppression. G-CSF support permitted further dose escalation of cisplatin and topotecan. Nonhematologic toxicities, primarily fatigue, nausea/vomiting, and neurosensory neuropathy, were observed but were generally mild. Of 15 patients assessable for response, nine had a complete response, four achieved a partial response, and two had stable disease. CONCLUSION: Neutropenia was the DLT of this combination of paclitaxel, cisplatin, and topotecan. The recommended phase II dose is paclitaxel 110 mg/m2 (day 1), followed by cisplatin 75 mg/m2 (day 2) and topotecan 0.3 mg/m2/d (days 2 to 6) with G-CSF support repeated every 3 weeks.  (+info)

Breast cancer is the leading cause of cancer in women in China. Preoperative chemotherapy for treatment of locally advanced breast cancer has become a standard therapy. Results from neoadjuvant trials have shown that pathological complete response (pCR) is an independent predictor of outcome. Paclitaxel was introduced into clinical practice in the early 1990s and has demonstrated good activity in the adjuvant and metastatic settings. Platinum complexes, like cisplatin and carboplatin, are active in a wide range of solid tumors. Paclitaxel combined with carboplatin has shown great activity in ovarian and nonsmall- cell lung cancer treatment. In addition, the overall response rate of paclitaxel plus carboplatin was between 53% and 62% in the first-line treatment of metastatic breast cancer. This study will evaluate the pCR rate of weekly paclitaxel plus carboplatin as preoperative treatment for breast cancer patients ...
In August 2009, during a major restructuring activity, BMS acquired the biotechnology firm Medarex as part of the companys String of Pearls strategy of alliances, partnerships and acquisitions.[28] In November, Bristol-Myers Squibb announced that it was splitting off Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move was expected to further sharpen the companys focus on biopharmaceuticals. In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas. Bristol-Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce Hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitexs shareholders acceptance of 126 percent premium price of its price over the previous 20 trading days ended on ...
Disclosure of Interest T. W. J. Huizinga Grant/research support from: EU & Dutch Arthritis Foundation, Consultant for: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Crescendo Bioscience, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, UCB, Inc., Eli Lilly, Meteor Board, Speakers bureau: Abbott Laboratories, Biotest AG, Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche, sanofi-aventis, Schering-Plough, S. E. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, A. Johnsen Employee of: Bristol-Myers Squibb, J. Zhu Employee of: Bristol-Myers Squibb, D. E. Furst Grant/research support from: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Consultant for: AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Cytori, Janssen, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, Speakers bureau: (CME only) AbbVie, Actelion, UCB, V. P. ...
Get information, facts, and pictures about Bristol-Myers Squibb Company at Encyclopedia.com. Make research projects and school reports about Bristol-Myers Squibb Company easy with credible articles from our FREE, online encyclopedia and dictionary.
PRIMARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior death rate when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. SECONDARY OBJECTIVES:. I. To determine if treatment with combination paclitaxel and carboplatin (TC) chemotherapy does not result in an inferior progression-free survival when compared to ifosfamide, mesna, and paclitaxel chemotherapy.. II. To determine if acute toxicity, specifically physician-assessed neurotoxicity and infection, associated with combination paclitaxel and carboplatin chemotherapy is reduced compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. III. To determine if treatment with combination paclitaxel and carboplatin chemotherapy is associated with superior patient-reported quality of life and neurotoxicity scores compared to that of ifosfamide, mesna, and paclitaxel chemotherapy.. TERTIARY OBJECTIVES:. I. To bank formalin-fixed, ...
TY - JOUR. T1 - Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint. AU - Sudo, Tamotsu. AU - Nitta, Masayuki. AU - Saya, Hideyuki. AU - Ueno, Naoto T.. PY - 2004/4/1. Y1 - 2004/4/1. N2 - Paclitaxel stabilizes microtubules, causing mitotic arrest and activating the spindle assembly checkpoint. We determined whether suppression of the checkpoint genes Mad2 and BubR1 affects paclitaxel resistance and whether overexpression of Mad2 protein in checkpoint-defective cells enhances paclitaxel sensitivity. Suppression of Mad2 and BubR1 in paclitaxel-treated cancer cells abolished checkpoint function, resulting in paclitaxel resistance that correlated with suppression of cyclin-dependent kinase-1 activity. In contrast, overexpression of Mad2 in cells with a checkpoint defect attributable to low Mad2 expression restored checkpoint function, resulting in enhanced paclitaxel sensitivity that correlated with enhanced cyclin-dependent kinase-1 activity. However, overexpression of ...
... NEW BRUNSWICK N.J. Nov. 30 /- Underscorin...The Bristol-Myers Squibb Pediatric Infectious Disease and ImmunologyC... At Bristol-Myers Squibb we believe that together we can prevail over...The new infectious disease and immunology center is the latest example...,Bristol-Myers,Squibb,,New,Jersey,Childrens,Hospital,Launch,Center,for,Immune,System,Disorders,&,Infectious,Diseases,Including,HIV/AIDS,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
BACKGROUND: Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity. METHODS: A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. All statistical tests were two-sided. RESULTS: Src family and Abl kinases were identified as modulators of paclitaxel sensitivity in SKOv3 cells. The siRNA knockdown of Src, Fyn, or Abl1 enhanced paclitaxel-mediated growth inhibition in ovarian cancer cells compared with a control
OREANDA-NEWS. Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. Validation of the application confirms the submission is complete and begins the EMAs centralized review process.. The high frequency of metastatic urothelial carcinoma and its relapsing nature highlight the substantial need for new treatment approaches with high and durable responses, said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. We look forward to working with the EMA to potentially extend the use of Opdivo and bring the science of Immuno-Oncology to help patients in Europe fight this difficult-to-treat, advanced form of bladder cancer.. The application primarily included data from ...
Author Disclosures: C.N. Hess: None. S. James: Research Grant; Significant; AstraZeneca. Other Research Support; Modest; The Medicines Company, Correvio, Sanofi. Consultant/Advisory Board; Modest; Sanofi. D.M. Wojdyla: None. R.D. Lopes: Research Grant; Significant; Bristol-Myers Squibb, GlaxoSmithKline. Consultant/Advisory Board; Modest; Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer. D. Liaw: Employment; Significant; Bristol-Myers Squibb. E. Hagstrom: Honoraria; Significant; Sanofi. D.L. Bhatt: Research Grant; Significant; Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, The Medicines Company. S. Husted: Research Grant; Significant; GlaxoSmithKline, Pfizer. Consultant/Advisory Board; Modest; Bayer, AstraZeneca, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim. S.G. Goodman: Research Grant; Significant; AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Pfizer, Sanofi. Honoraria; ...
mmuno-Oncology (I-O), and the research behind it, aspires to beat cancer at its own game. In February 2017, it was named advance of the year for a second year in a row by the American Society of Clinical Oncology (ASCO). The sheer amount of translational research underway with groundbreaking I-O approaches is very exciting, says Steven Averbuch, vice president, Translational Clinical Development & Pharmacodiagnostics at Bristol-Myers Squibb.. But despite the progress to date, less than 50 percent of patients respond to I-O, depending on the patient population and the specific types of cancers involved. A stat like that begs the question: Why do some people respond to immunotherapies while others dont?. Building on knowledge gleaned from nearly 20 years of researching immunotherapies, Bristol-Myers Squibb scientists are hunting for answers to that question at an accelerated pace with the help of cutting-edge technologies. They are investigating the biology of cancer and the immune system at ...
Using NOVO-DENTOCAINE LIQ 65MG/ML during pregnancy may raise the risk of children developing some disorder (commpon for some such kind of drugs), however it depends upon how NOVO-DENTOCAINE LIQ 65MG/ML ingredients pass through placenta and may have effect on baby - Strength of NOVO-DENTOCAINE LIQ 65MG/ML is major factor in determination of such side effects, The possible danger in pregnancy are under research. BRISTOL-MYERS SQUIBB, S.A Canada publish leaflet about NOVO-DENTOCAINE LIQ 65MG/ML every update to describe possible risks of using NOVO-DENTOCAINE LIQ 65MG/ML side effect in pregnancy and pregnant women. You may download BRISTOL-MYERS SQUIBB, S.A issued leaflet regarding side effects of NOVO-DENTOCAINE LIQ 65MG/ML - BENZOCAINE. Pregnancy Side Effects can be easily know by Atc code of NOVO-DENTOCAINE LIQ 65MG/ML ATC CODE.. ...
Faculty Disclosure. Dr Kane has been a consultant for Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has received honoraria from Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has been on the speakers/advisory boards for Bristol-Myers Squibb, Genentech, and Otsuka; and has been a stock shareholder in MedAvante.. Dr Correll has been a consultant for Bristol-Myers Squibb, Eli Lilly, Gerson Lehrman Group, Intra-Cellular Therapies, Lundbeck, MedAvante, Pfizer, ProPhase, Otsuka, Sunovion, and Vanda; has received grant/research support from Bristol-Myers Squibb, Janssen, Johnson & Johnson, Novo Nordisk A/S, and Otsuka; has received honoraria from Medscape; has been on the speaker/advisory boards of Alexza, Bristol-Myers Squibb, Eli Lilly, Genentech, Intra-Cellular Therapies, Lundbeck, Merck, ...
CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership for TARGET-NASH to a multi-year agreement. Bristol-Myers Squibb is committed to the discovery and development of
In this study, evidence has been collected that supports the notion that paclitaxel may exert its toxicity via elevation of intracellular O2−, H2O2, and NO levels. This theory is confirmed by our data showing that (a) paclitaxel induced the production of O2−, H2O2 and NO; (b) paclitaxel induced oxidative DNA damage; (c) agents that decreased H2O2 and NO production suppressed paclitaxel-induced DNA damage, G2-M arrest, apoptosis, and cell growth inhibition; (d) inhibition of SOD or glutamylcysteine synthase increased paclitaxel-induced apoptosis; (e) cell lines with higher total antioxidant capacity were more resistant to paclitaxel cytotoxicity; and (f) agents that decreased clonogenic survival in paclitaxel-treated cells also decreased cellular total antioxidant capacity. Thus, paclitaxel chemoresistance correlates very well to intracellular antioxidant capacity.. Kong et al. ( 27) speculated that many chemotherapeutic agents exert their toxic effects on cancer cells by producing free ...
Disclosure of Interest R. Alten Grant/research support from: BMS, Merck Pharma GmbH, Wyeth Pharmaceuticals, Pfizer, Consultant for: Abbott Laboratories, Horizon Pharma, Merck Pharma GmbH, Nitec Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, Speakers bureau: Abbott Laboratories, BMS, Horizon Pharma, Merck Pharma GmbH, Novartis Pharmaceuticals Corporation, Roche, M. Hochberg Grant/research support from: NIH, Consultant for: Abbott Laboratories, Amgen Inc., BMS, Eli Lilly and Company, EMD Serono Inc., Genentech/Roche, Merck & Co., Inc., Novartis Pharma AG, Pfizer Inc, Speakers bureau: Bioberica SA, IBSA, Rottapharm/Madaus, R. Cohen Consultant for: Bristol-Myers Squibb, M. Weinblatt Grant/research support from: Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Abbott, J. Kaine Grant/research support from: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, UCB, E. Keystone Grant/research support from: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP;, ...
TY - JOUR. T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma. T2 - A Gynecologic Oncology Group Study. AU - Mannel, Robert S.. AU - Brady, Mark F.. AU - Kohn, Elise C.. AU - Hanjani, Parviz. AU - Hiura, Masamichi. AU - Lee, Roger. AU - DeGeest, Koen. AU - Cohn, David E.. AU - Monk, Bradley J.. AU - Michael, Helen. PY - 2011/7/1. Y1 - 2011/7/1. N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment ...
Bristol-Myers Squibb Company (NYSE:BMY) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a collaborative clinical trial to evaluate the combination of Bristol-Myers Squibbs immunotherapy Opdivo (nivolumab) and Daiichi Sankyos investigational antibody drug conjugate DS-8201 in HER2-expressing metastatic breast and urothelial (bladder) cancers. We are excited to evaluate if the combination of these two mechanisms of action - the ability of an anti-PD-1 to harness the immune system and the potential of DS-8201 to deliver chemotherapy directly to target cancer cells - may be able to improve the outcomes of patients with HER2-expressing advanced breast and bladder cancer, said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. Pursuing combination studies like this is at the core of the Daiichi Sankyo Cancer Enterprise strategy, as we are looking to maximize the potential of our proprietary antibody ...
FDA Approves Sanofi-Aventis and Bristol-Myers Squibb New 300mg Loading Dose Tablet for PLAVIX BRIDGEWATER and PRINCETON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Sanofi-aventis and Bristol-Myers
April 5, 2013. -Two Phase 2 studies to evaluate once-daily combination of Vertexs investigational nucleotide analogue VX-135 and BMS investigational NS5A replication complex inhibitor daclatasvir-. -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013-. -Study in people with genotypes 1, 2 and 3 hepatitis C, including people with cirrhosis, planned for second half of 2013-. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb Company (NYSE: BMY) to conduct Phase 2 studies of once-daily all-oral treatment regimens containing Vertexs nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Bristol-Myers Squibbs NS5A replication complex inhibitor daclatasvir for the treatment of hepatitis C. As part of the agreement, Vertex plans to conduct two Phase 2 studies of the combination, including an initial study in ...
TY - JOUR. T1 - Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer. T2 - a phase 3, open-label, randomised controlled trial. AU - Katsumata, Noriyuki. AU - Yasuda, Makoto. AU - Takahashi, Fumiaki. AU - Isonishi, Seiji. AU - Jobo, Toshiko. AU - Aoki, Daisuke. AU - Tsuda, Hiroshi. AU - Sugiyama, Toru. AU - Kodama, Shoji. AU - Kimura, Eizo. AU - Ochiai, Kazunori. AU - Noda, Kiichiro. N1 - Funding Information: SI and DA have received honoraria from Bristol-Myers Squibb. DA and HT have received grant support from Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest. Funding Information: This study was funded by an unrestricted grant from Bristol-Myers Squibb. We thank the women who participated in this trial and Akihiro Yanagisawa, Kei Matsubara for assisting protocol design and review, Keiichi Fujiwara for internal auditing, and Robert F Ozols for protocol design and manuscript review. PY - 2009. Y1 - ...
Health,PRINCETON NJ -- Bristol-Myers Squibb has awarded a five-year $500000...Jeffrey S. Flier M.D. whose research in diabetes and obesity has ...Simeon Taylor M.D. Ph.D. vice president of Cardiovascular and Me... Dr. Taylor praised the discoveries and insights provided by Dr. Fl...,Unrestricted,metabolic,research,grant,awarded,to,Beth,Israel,Deaconess,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
LOS ANGELES--Interim analysis of a major German-Austrian trial comparing cisplatin (Platinol)/paclitaxel (Taxol) with carboplatin (Paraplatin)/paclitaxel as first-line treatment in ovarian cancer found significantly less toxicity with carboplatin/paclitaxel, with no apparent loss of efficacy. 1
Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients
Grant Support: By the National Heart, Lung, and Blood Institute (contract N01-HC-35130). The ALLHAT investigators received study medications from Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin) and financial support from Pfizer.. Potential Financial Conflicts of Interest:Consultancies: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed); Honoraria: B.R. Davis (Pfizer), J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Merck & Co., Novartis Pharma AG, Pfizer, Phoenix Pharmaceuticals, Searle & Co., SmithKline Beecham, Solvay/Unimed), P. Whelton (Pfizer); Grants received: J.T. Wright Jr. (Astra, Aventis, Bayer, Bristol-Myers Squibb, Eli Lilly & Co., Merck & Co., Novartis Pharma AG, Pfizer, Searle & Co., SmithKline Beecham, Solvay/Unimed); J.A. Cutler (Pfizer, AstraZeneca, Bristol-Myers ...
We believe that combination therapy may provide an important opportunity to address the needs of every patient with first-line lung cancer.. Previous studies with Opdivo have shown benefit and supported the approval of Opdivo for indications in several types of cancer, including previously treated metastatic non-small cell lung cancer. Patients who are being treated with Opdivo should continue their therapy as prescribed and consult with their healthcare provider in all aspects of care.. Everyone at Bristol-Myers Squibb is relentless in our pursuit to defeat cancer and bring transformational medicines to patients who are waiting.. U.S. FDA APPROVED INDICATIONS FOR OPDIVO®. OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.. OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved ...
TY - JOUR. T1 - Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. AU - Nguyen, Dao M.. AU - Chen, G. Aaron. AU - Reddy, Rishindra. AU - Tsai, Wilson. AU - Schrump, William D.. AU - Cole, George. AU - Schrump, David S.. AU - Jones, David A.. AU - Mentzer, Steven J.. AU - Harpole, David H.. PY - 2004/2. Y1 - 2004/2. N2 - Background: Constitutive activation of the phosphoinositide 3-kinase/protein kinase B survival signal transduction pathway influences the intrinsic chemoresistance of cancer cells. This study evaluates the effect of LY294002, a pharmacologic inhibitor of phosphoinositide 3-kinase, on the sensitivity of lung and esophageal cancer cells to paclitaxel (Taxol) in vitro. Materials and Methods: Cell viability and apoptosis of cancer cells treated with paclitaxel + LY294002 combinations were quantitated by methyl-thiazol-diphenyl-tetrazolium and ...
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors
Were midway through the week and things have already been moving pretty fast. Action across the biotechnology sector is dictated by a variety of inputs but development stage pipeline updates are where the real action lies and - as we head into the bell on Wednesday - there are a couple of key pipeline related events that are going to set sentiment for the day. Heres a look at which companies are moving, whats moving each and whats next for the companies in question.. The two companies in focus for the session today are Bristol-Myers Squibb Company (NYSE:BMY) and Portola Pharmaceuticals Inc. (NASDAQ:PTLA).. First up, then, BMS.. After the closing bell rang on Tuesday, BMS announced top line data from a study called CheckMate-214. The trial was set up to investigate the potential use of Opdivo (nivolumab) in combination with Yervoy (ipilimumab), as compared to an already approved (and pretty well established) standard of care drug called sunitinib. The target indication in this instance was ...
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail against serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis. Additionally, our philanthropic programs have given new hope to some of the worlds most vulnerable communities and the preservation of our natural resources represents one of our key commitments. Our BioPharma strategy uniquely combines the best elements of a traditional pharmaceutical company with the entrepreneurial spirit and agility of a leading-edge biotech company - and our strategy is working. Since 2002, we have delivered 13 key new products to patients with serious diseases, four of these medicines are biologic products, and our pipeline continues to deliver. In 2011, we received approvals ...
FDA Approved Daklinza (Daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3. http://news.bms.com/press-release/fda-approves-daklinza-daclatasvir-treatment-patients-chronic-hepatitis-c-genotype-3, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Financial Help Info for Daklinza (daclatasvir) . http://www.daklinza.bmscustomerconnect.com/support, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Highlights of Prescribing Information - DAKLINZA. http://packageinserts.bms.com/pi/pi_daklinza.pdf, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. Patient Support Connect. http://www.patientsupportconnect.bmscustomerconnect.com/, Bristol-Myers Squibb Company. Retrieved July 27, 2015.. ...
Home » Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicines Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy ...
This Boston Biotech Just Got Scooped Up for $300M By Bristol-Myers Squibb - read this article along with other careers information, tips and advice on BioSpace
Product Details :: Buy Plavix by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, British Dispensary, Bayer, Lilly: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com
Product Details :: Buy Bespar by Bristol-Myers Squibb - Buy real authentic Steroids online, anabolic steroids, Injectable Steroids, Oral Steroids, anti estrogens, HGH & Peptides steroids by Geneza Pharmaceuticals, Biomex Labs, Asia Pharma, Balkan Pharmaceuticals, Flonase, Casablanca Pharmaceuticals: - buy anabolic steroids, buy Injectable Steroids, buy Oral Steroids, buy anti estrogens, buy HGH & Pept - https://www.authenticpharm.com
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough
Source: S&P Capital IQ. TTM = trailing 12 months.. Unfortunately, that table doesnt tell us much about where Bristol-Myers Squibb has been, or where its going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it cant make up for this problem by cutting costs -- and most companies cant -- then both the business and its shares face a decidedly bleak outlook.. Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a companys profitability. Thats why I like to look at five fiscal years worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter. You cant always reach a hard ...
Multilind Suspension information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Multilind Suspension indications, usages and related health products lists
Explore comprehensive information about Bristol-Myers Squibb products including dosage and safety information. Learn more about our medicines today.
Stomahesive Powder information about active ingredients, pharmaceutical forms and doses by Bristol-Myers Squibb, Stomahesive Powder indications, usages and related health products lists
American pharmaceutical giant Bristol-Myers Squibb is set to buy US biotech company Inhibitex in a $2.5bn (£1.6bn) deal, bolstering its portfolio of drugs targeting the burgeoning hepatitis C market.
Former Bristol-Myers Squibb executive Robert Ramnarine of East Brunswick, N.J., pleaded guilty Monday in federal court in Trenton to charges that he got rich by using advance knowledge of the companys pending acquisition on Amylin in 2012. - David Sell, Philadelphia Inquirer
Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the
Drug firm, subsidiary settle suits for $515m Pricing schemes, fraud alleged By Jonathan Saltzman and Liz Kowalczyk, Globe Staff | September 29, 2007 Bristol-Myers Squibb and a subsidiary...
PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--April 27, 2006--Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of a product that combines the anti-HIV medications Sustiva(R) (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences, in a once-daily single tablet regimen. Truvada itself is a fixed-dose product that contains two of Gileads anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine), in a single once-daily tablet. If approved by the FDA, the new single tablet regimen would be the first and only product that contains a complete Highly Active Antiretroviral Therapy (HAART) regimen in a single once-daily tablet, intended for the treatment of HIV-1 infection in adults as a complete regimen or in ...
Using DERMOPLAST AEROSOL SPRAY during pregnancy may raise the risk of children developing some disorder (commpon for some such kind of drugs), however it depends upon how DERMOPLAST AEROSOL SPRAY ingredients pass through placenta and may have effect on baby - Strength of DERMOPLAST AEROSOL SPRAY is major factor in determination of such side effects, The possible danger in pregnancy are under research. BRISTOL-MYERS SQUIBB, S.A Canada publish leaflet about DERMOPLAST AEROSOL SPRAY every update to describe possible risks of using DERMOPLAST AEROSOL SPRAY side effect in pregnancy and pregnant women. You may download BRISTOL-MYERS SQUIBB, S.A issued leaflet regarding side effects of DERMOPLAST AEROSOL SPRAY - BENZOCAINE. Pregnancy Side Effects can be easily know by Atc code of DERMOPLAST AEROSOL SPRAY ATC CODE.. ...
OBJECTIVES: To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.. METHODS: 8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity. The effect of the combinations was also evaluated by measuring the inhibition of cells grown as spheroids.. RESULTS: Navitoclax exhibited modest (IC(50)=3-8 μM) single agent potency. Antagonism between carboplatin and paclitaxel was evident in Ovcar-4, Ovcar-8 and Skov-3 cells. Drug combinations including navitoclax with carboplatin and/or paclitaxel showed significantly less antagonism, or even synergy, in several cell lines than carboplatin/paclitaxel alone. Navitoclax enhanced the activation of caspase 3/7 induced by carboplatin and/or paclitaxel in Igrov-1 cells. Combinations of navitoclax, carboplatin and paclitaxel showed more than additive activity ...
Ampullary carcinoma is a rare tumor and evidence on the treatment of recurrent metastatic disease is scarce. We report the case of a 60-year-old patient with an R0-resected node-positive adenocarcinoma of the papilla of Vater of an initially diagnosed intestinal subtype who developed pulmonary metastases 2 months after adjuvant gemcitabine chemotherapy and, subsequently, liver metastases. Palliative combination chemotherapy with standard regimens for intestinal-type adenocarcinoma (FOLFOX and FOLFIRI) failed. However, subsequent combination chemotherapy with nanoparticle albumin-bound paclitaxel and gemcitabine, a regimen with proven efficacy in metastatic adenocarcinoma of the pancreas, resulted in a durable, very good partial remission. Treatment was manageable and well tolerated. Primary tumor and metastatic tissue were reassessed by immunohistochemistry and had to be reclassified to a mixed phenotype containing predominant elements of the pancreatobiliary subtype. Our case suggests that combination
Looking for online definition of Paclitaxel/Carboplatin or what Paclitaxel/Carboplatin stands for? Paclitaxel/Carboplatin is listed in the Worlds largest and most authoritative dictionary database of abbreviations and acronyms
Bristol-Myers Squibb Company (NYSE: BMY) and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers
TY - JOUR. T1 - A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. AU - Chen, Y. M.. AU - Perng, R. P.. AU - Shih, J. F.. AU - Lee, Y. C.. AU - Lee, C. S.. AU - Tsai, C. M.. AU - Whang-Peng, J.. PY - 2004/1/26. Y1 - 2004/1/26. N2 - Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m -2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, or V 23 mg m-2 i.v. on days 1, 8, and 15, and C 60 mg m-2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to ...
This page contains abstract Effects of Gamma-linolenic Acid and Oleic Acid on Paclitaxel Cytotoxicity in Human Breast Cancer Cells http://www.chiro.org/nutrition/ABSTRACTS/Effects_of_Gamma_linolenic_Acid.shtml
TY - JOUR. T1 - A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. AU - Schiller, J. H.. AU - Storer, B.. AU - Tutsch, K.. AU - Arzoomanian, R.. AU - Alberti, D.. AU - Feierabend, C.. AU - Spriggs, D.. PY - 1994/11/3. Y1 - 1994/11/3. N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once ...
On September 27, 2012, Justice Barnes of the Federal Court granted Bristol-Myers Squibb (BMS) an Order prohibiting the Minister of Health from issuing a notice of compliance (NOC) to Mylan Pharmaceuticals ULC for a generic efavirenz product (BMSs SUSTIVA) until the expiry of Patent No. 2,101,572 ( 572), but not Patent No. 2,279,198 ( 198). Canada Intellectual Property Smart & Biggar/Fetherstonhaugh 15 Oct 2012
Bristol-Myers Squibb was developing inosine monophosphate dehydrogenase (IMPDH) inhibitors for the prevention of solid organ transplant rejection and for the
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance
TY - JOUR. T1 - Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. AU - Xiong, Xiaoxiong. AU - Sui, Meihua. AU - Fan, Weimin. AU - Kraft, Andrew S.. N1 - Funding Information: This work was supported in part by NIH grant and CA92280 (to W.F.).. PY - 2007/7. Y1 - 2007/7. N2 - The combination of carboplatin and paclitaxel is widely used to treat multiple solid tumors including ovarian, lung and breast cancer. Usually these drugs are given simultaneously with little regard to the importance of scheduling to obtain a maximal response. To investigate the importance of sequencing, the human breast Bcap37 and ovarian OV2008 cancer cell lines were exposed to carboplatin and paclitaxel in three different sequences: (1) pretreatment with paclitaxel followed by carboplatin, (2) pretreatment of carboplatin followed by paclitaxel and (3) simultaneous treatment with these two agents. The combination of carboplatin and paclitaxel resulted in antagonistic ...
Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to
TY - JOUR. T1 - Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. AU - Miller, Kathy D.. AU - Sisk, Judy. AU - Ansari, Rafat. AU - Gize, Gary. AU - Nattam, Sreenivasa. AU - Pennington, Kenneth. AU - Monaco, Frank. AU - Sledge, George W.. PY - 2001/12/1. Y1 - 2001/12/1. N2 - A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity ...
BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the companys New Drug Application (NDA) for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm.. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded ...
Japans largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
Studies suggest that ω-3 polyunsaturated fatty acids (PUPAs) are beneficial in inhibiting the growth of cancer cells and may enhance the cytotoxicity induced by certain chemotherapeutic agents. It is known that seal oil is rich in ω-3 PUPAs. The effect of seal oil and its role on the cytotoxicity and apoptosis induced by paclitaxel was, therefore, investigated in breast cancer cell lines, MCF-7 and MDA-MB-231. -- MCF-7 and MDA-MB-231 cells were respectively treated with seal oil, paclitaxel, and paclitaxel in combination with seal oil. Cytotoxicity was evaluated by MTT assay. Apoptosis was investigated by morphological changes and DNA strand break assay. Western blot assay was used to assess the expression of p53 and Bcl-2 proteins. The lipid peroxide products were measured by thiobarbituric acid reactive substances (TEARS) assay and the intracellular lipid composition was determined by gas chromatography (GC). -- MTT assay showed that seal oil induced cell death and enhanced paclitaxel ...
In September of 2011, Ambrx entered into a worldwide collaboration with Bristol-Myers Squibb to develop and commercialize product candidates surrounding the Fibroblast Growth Factor 21 (FGF-21) protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure. Derivatives of FGF-21 and Relaxin were developed using Ambrxs unique ReCODE™ platform technology to modify the native proteins with amino acid building blocks beyond the 20 naturally occurring amino acids. Bristol-Myers Squibb and Ambrx also entered into research collaborations for both programs, which focus on engineering enhanced versions of the two target proteins for therapeutic use. In May of 2013, Ambrx entered into a collaboration agreement with Bristol-Myers Squibb for the discovery and development of novel antibody drug conjugates using Ambrxs Protein Medicinal Chemistry™ technology. These drug candidates will be based on Ambrxs EuCODE™ technology.. Read Press ...
TY - JOUR. T1 - Dicer elicits paclitaxel chemosensitization and suppresses cancer stemness in breast cancer by repressing AXL. AU - Chang, Ting Yu. AU - Chen, Hsin An. AU - Chiu, Ching Feng. AU - Chang, Yi Wen. AU - Kuo, Tsang Chih. AU - Tseng, Po Chun. AU - Wang, Weu. AU - Hung, Mien Chie. AU - Su, Jen Liang. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Paclitaxel is a standard-of-care chemotherapy for breast cancer, despite the increasing recognition of its poor effectiveness in the treatment of patients with advanced disease. Here, we report that adenovirus-type 5 E1A-mediated elevation of the miRNA-processing enzyme Dicer is sufficient to enhance paclitaxel sensitization and reduce cancer stem-like cell properties in this setting. Elevating Dicer expression increased levels of the AXL kinase targeting miRNA miR-494, thereby repressing AXL expression to increase paclitaxel sensitivity. We found that Dicer expression was regulated at the transcription level by E1A, through activation of an MAPK14/CEBPα ...
PALIFERMIN, Palifermin, Paclitaxel protein-bound, PACLITAXEL, Paclitaxel, p24, Online Electronic Medical Diagnosis and Drugs, Medications, Articles, Glossary
TY - JOUR. T1 - Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. AU - Comella, Pasquale. AU - Gambardella, Antonio. AU - Frasci, Giuseppe. AU - Avallone, Antonio. AU - Costanzo, Raffaele. AU - Gridelli, Cesare. AU - Stupp, Roger. AU - Scagliotti, Giorgio V.. AU - Comella, P.. AU - Frasci, G.. AU - Avallone, A.. AU - Costanzo, R.. AU - Gambardella, A.. AU - Bianco, M.. AU - Bilancia, D.. AU - Buzzi, F.. AU - Bartolucci, R.. AU - Cioffi, R.. AU - Messina, V.. AU - Carnicelli, P.. AU - De Cataldis, G.. AU - Del Gaizo, F.. AU - Del Prete, S.. AU - Di Lullo, L.. AU - Farris, A.. AU - Putzu, C.. AU - Filippelli, G.. AU - Olivito, V.. AU - Dima, G.. AU - Guida, M.. AU - Iannelli, A.. AU - Condemi, G.. AU - Mancarella, S.. AU - Maiorino, L.. AU - Musicò, M.. AU - Massidda, B.. AU - Ionta, M. ...
Purpose: Low-dose metronomic chemotherapy treatments, especially when combined with dedicated antiangiogenic agents, can induce significant antitumor activity without serious toxicity in various preclinical models. It remains unclear, however, whether some cytotoxic drugs are better suited for metronomic regimens than others. Paclitaxel appears to be a strong candidate for metronomic chemotherapy given its ability to inhibit endothelial cell functions relevant to angiogenesis in vitro at extraordinarily low concentrations and broad-spectrum antitumor activity. Clinically relevant concentrations of the formulation vehicle cremophor EL in Taxol, however, were previously reported to nullify the antiangiogenic effect of paclitaxel, the result of which would hamper its usefulness in metronomic regimens. We hypothesized that ABI-007, a cremophor EL-free, albumin-bound, 130-nm form of paclitaxel, could potentially alleviate this problem.. Experimental Design: The antiangiogenic activity of ABI-007 ...
Paclitaxel appears to be a potential substrate of the multidrug resistance protein p-glycoprotein, thus preventing itself from entry into the brain and penetrating blood-brain barrier poorly. In this study, the main objective was to design paclitaxel formulation using PLGA-based nanoparticles with different additives and surface coatings to facilitate the paclitaxel transport through MDCK cell monolayer. PLGA-based nanoparticles of around 200 nm without and with additives and surface coatings were developed by direct dialysis. The transendothelial electrical resistance (TEER) variation of MDCK cell monolayer on the cell inserts imposed by paclitaxel-loaded nanoparticles with and without additives was investigated. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) (MTT) assay was used to quantify the cell viability of C6 glioma cells after administration of formulations on the topical side. Investigations showed that particles with additives were able to enhance cellular ...
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast cancer. It is yet unclear whether addition of capecitabine to the combination of these drugs improves the treatment outcome. Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(A (R))) and paclitaxel (Taxol(A (R))) alone (ET) or in combination with capecitabine (Xeloda(A (R)), TEX). Starting doses for ET were epirubicin 75 mg/m(2) plus paclitaxel 175 mg/m(2), and for TEX epirubicin 75 mg/m(2), paclitaxel 155 mg/m(2), and capecitabine 825 mg/m(2) BID for 14 days. Subsequently, doses were tailored related to side effects. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life (QoL). 287 patients were randomized, 143 to ET and 144 to TEX. Median PFS was 10.8 months for patients treated with ET, and ...
BACKGROUND: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx trade mark ) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics of PLD in this combination. METHODS: A phase I study was performed with an initial dose of 50 mg/m(2) wPTX and 30 mg/m(2) PLD. The paclitaxel dose was escalated in increments of 10 mg/m(2) and PLD in increments of 5 mg/m(2) until the MTD was reached. The pharmacokinetics of PLD were studied at the highest achieved dose levels. RESULTS: Forty-four cancer patients were enrolled. The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX. Dose-limiting toxicities included treatment delay for neutropenia grade 3, febrile neutropenia, palmar-plantar erythrodysesthesia and deep venous thrombosis. Toxicity below the MTD was mild: skin toxicity grade 1-2 developed at high cumulative doses and vascular thrombotic events occurred in two patients with predisposing factors. No ...
At a median follow-up of 2.1 years, 23 patients had died. Of 10 patients in the intervention group, 2 died of renal cell carcinoma; of 13 in the active surveillance group, none died of the disease.. The cancer-specific survival rate exceeded 99% in both arms. Five-year overall survival was 92% with primary intervention and 75% for active -surveillance.. Two Paclitaxel Regimens Compared. In the treatment of breast cancer, dose-dense paclitaxel is often assumed to be more toxic than weekly paclitaxel, but investigators from Edwards Comprehensive Cancer Center in Huntington, West Virginia, reported that the regimens have a comparable tolerability profile.2. Mohamed Alsharedi, MD, suggested that some clinicians favor weekly paclitaxel because they deem the toxicities to be more than with dose-dense paclitaxel, based on the profile observed with weekly paclitaxel in the SWOG S0221 trial.3 To make treatment duration equal, however, SWOG S0221 tested six cycles of dose-dense paclitaxel, not four, which ...
Patients and Methods Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m2 on days 1, 8, and 15 plus cisplatin 60 mg/m2 on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m2 plus carboplatin area under the curve 6.0 mg/mL/min on day 1 every 3 weeks for six cycles (TC group). The primary end point was progression-free survival. Secondary end points were overall survival, overall response rate, and adverse events ...
Abraxane use in ovarian cancer, abraxane with tykerb, abraxane billing code, abraxane blood brain barrier and abraxane oncology. Abraxane carboplatin, abraxane mixing, abraxane 2008 sales and abraxane gradishar or abraxane cost.
TY - CONF. T1 - Gemcitabine resistant pancreatic cancer cells are sensitive to paclitaxel treatment. AU - Le Large, TYS. PY - 2017. Y1 - 2017. M3 - Poster. ER - ...
The combination of carboplatin-paclitaxel is a global standard following recent consensus recommendations [20, 4]. Although this treatment is highly effective, most patients recur. The majority are platinum-sensitive at first relapse, thus, candidates for re-treatment with platinum. Indeed, these patients will be generally re-treated with a platinum-taxane combination, especially in the light of recent trials showing advantage over platinum monotherapy [9]. However, the cumulative neurotoxicity of both drugs, as well as the increased risk of neurotoxicity for patients in relapse and the further experience of alopecia, are essential considerations when selecting second-line therapy [21]. As treatment at relapse is rarely curative, toxicity, tolerance, ease of administration and QoL should be interrelated to efficacy and survival prolongation when novel platinum-based combinations are evaluated for patients with platinum-sensitive OC.. This study was originally designed in 1999, in an era when ...
Paclitaxel, in contrast, is a tubulin polymerization stabilizer and is used as a chemotherapeutic drug. Paclitaxel is based on ... Sneader W (2005). "Paclitaxel (taxol)". Drug Discovery: A History (Rev. and updated ed.). Chichester: Wiley. pp. 112-113. ISBN ... An example of this is paclitaxel, which can be manufactured by extracting 10-deacetylbaccatin III from T. brevifolia needles, ... Clinically useful examples include the anticancer agents paclitaxel and omacetaxine mepesuccinate (from Taxus brevifolia and ...
FDA (October 2012). "Highlights of Prescribing Information, Abraxane for Injectable Suspension" (PDF). "Paclitaxel (Abraxane ... is the nanoparticle albumin bound paclitaxel. Doxil was originally approved by the FDA for the use on HIV-related Kaposi's ...
Gibson JD, Khanal BP, Zubarev ER (September 2007). "Paclitaxel-functionalized gold nanoparticles". Journal of the American ... Gold nanoparticles are being investigated as carriers for drugs such as Paclitaxel. The administration of hydrophobic drugs ...
Paclitaxel the active compound found in Taxol is a chemotherapy drug used to treat many forms of cancers including ovarian ... "Paclitaxel Monograph for Professionals". Drugs.com. Retrieved 2020-04-04. "Success Story: Taxol". dtp.cancer.gov. Retrieved ... The two most commonly known terpenoids are artemisinin and paclitaxel. Artemisinin was widely used in Traditional Chinese ...
". "Paclitaxel, Protein-Bound Suspension". Paclitaxel, Protein-Bound Suspension. Cancer.Org. January 6, 2015. Retrieved January ...
Horwitz SB (1994). "Taxol (paclitaxel): mechanisms of action". Annals of Oncology. 5 (Suppl 6): S3-6. PMID 7865431. Rao PN, ...
Liggins RT; Hunter WL; Burt HM (1 December 1997). "Solid-state characterization of paclitaxel". Journal of Pharmaceutical ...
... competes with paclitaxel for microtubule binding, but with higher affinity and is also effective in paclitaxel- ... Epothilone Paclitaxel Gunasekera, S. P.; Gunasekera, M.; Longley, R. E.; Schulte, G. K. J. Org. Chem. 1990, 55, 4912-4915. (doi ... and synergistic antiproliferative activity in combination with paclitaxel. Discodermolide was recognized as one of the most ...
Unlike standard taxanes (paclitaxel Taxol®; docetaxel (Taxotere®) that require slow intravenous administration and are ... tesetaxel demonstrated substantially higher activity against cancer cell lines that were resistant to paclitaxel and docetaxel ...
"The Merck Index Online: Paclitaxel". Royal Society of Chemistry. Retrieved 30 June 2014. "The Merck Index Online: Penicillin V ...
"Paclitaxel Protein-Bound - Chemotherapy Drugs - Chemocare". chemocare.com. Retrieved 2021-04-30. Rahbar S (October 1968). "An ...
"FDA approves Taxus paclitaxel-eluting stent". www.medscape.com/. Retrieved 20 Feb 2015. "Boston Scientific Closes Cameron ...
Everolimus-eluting versus paclitaxel-eluting stents. Kounis NG, Goudevenos JA. Lancet 2010;375:1160-3. Kounis NG, Evans WH. ...
Paclitaxel was originally derived from the Pacific yew tree. Taxanes are difficult to synthesize because of their numerous ... Paclitaxel (Taxol) and docetaxel (Taxotere) are widely used as chemotherapy agents. Cabazitaxel was FDA approved to treat ... Hoffman, Angela M; Shahidi, Fereidoon (January 2009). "Paclitaxel and other taxanes in hazel". Journal of Functional Foods. 1 ( ... "How Taxol/paclitaxel kills cancer cells". Molecular Biology of the Cell. 25 (18): 2677-2681. doi:10.1091/mbc.e14-04-0916. ISSN ...
"LDE225 and Paclitaxel in Solid Tumors". ClinicalTrials.gov. National Institutes of Health. 13 February 2014. Retrieved 16 ... "Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma". ...
Paclitaxel or Taxol can be produced. The tree can also be used in many other ways and is under special protection of national ...
carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC. IPASS studied 1,217 patients with confirmed adenocarcinoma ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ... September 2009). "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma". The New England Journal of Medicine. 361 ( ...
Docetaxel is a semisynthetic taxane and nab-paclitaxel is a nanoparticle albumin-bound paclitaxel. Paclitaxel Paclitaxel binds ... Nanoparticle Albumin-Bound Paclitaxel Nanoparticle albumin-bound (nab) paclitaxel is an Albumin bound with high affinity to the ... A recent meta-analysis showed that when compared to Paclitaxel, nab-paclitaxel has significant beneficial effects in terms of ... In 2018, the FDA approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line ...
AC-Taxol: AC followed by paclitaxel (Taxol). TAC: Taxotere (docetaxel), Adriamycin (doxorubicin), and cyclophosphamide. FEC: 5- ...
... or paclitaxel. Alitretinoin, applied to the lesion, may be used when the lesion are not getting better with standard treatment ... "Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma". Journal of Clinical Oncology. 17 ... "Mechanism of paclitaxel activity in Kaposi's sarcoma". Journal of Immunology. 165 (1): 509-17. doi:10.4049/jimmunol.165.1.509. ...
In March 2019, it was approved in the United States, in combination with paclitaxel protein-bound, for adults with unresectable ... "FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations". U.S. Food and ... The chemotherapy used was Carboplatin, and Paclitaxel. Median overall survival was 19.8 and 14.9 months for patients treated ... IMpower130 was an open-label, phase 3 trial that compared Atezolizumab in combination with carboplatin plus nab-paclitaxel ...
Sparreboom A, Verweij J (15 Jul 2003). "Paclitaxel Pharmacokinetics, Threshold Models, and Dosing Strategies". Journal of ...
... evofosfamide and protein-bound paclitaxel (nab-paclitaxel) have been investigated in combination with gemcitabine in patients ... The study CA046 compares gemcitabine with gemcitabine plus nab-paclitaxel. Gemcitabine is a generic product sold by many ... The indirect comparison of both studies shows comparable efficacy profiles of evofosfamide and nab-paclitaxel in combination ... protein-bound paclitaxel (Abraxane), marketed by Celgene; and FOLFIRINOX, which is a combination of generic products that are ...
He led the first clinical studies showing that paclitaxel was an effective therapy for Kaposi's sarcoma and that thalidomide ... Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26-28. Yarchoan Amherst Honorary Degree Description ...
Paclitaxel-used to treat lung cancer, ovarian cancer, breast cancer, and advanced forms of Kaposi's sarcoma. Docetaxel-used to ... Examples of mitotic inhibitors frequently used in the treatment of cancer include paclitaxel, docetaxel, vinblastine, ... "Treatment of HIV-associated Kaposi's sarcoma with paclitaxel". Lancet. 346 (8966): 26-28. doi:10.1016/S0140-6736(95)92654-2. ...
Selected terpenoids Paclitaxel is a diterpenoid anticancer drug. Terpineols are monoterpenoids. Humulones are classified as ...
Deng, Jiexin; Huang, Leaf; Liu, Feng (May 2010). "Understanding the structure and stability of paclitaxel nanocrystals". ... "Impact of surfactant treatment of paclitaxel nanocrystals on biodistribution and tumor accumulation in tumor-bearing mice". ...
T. andreanae produces paclitaxel, also known as taxol. This drug is important for the treatment of cancer. Other endophytes ... but to date there has been no successful industrial source of paclitaxel created. Endophytes have been discovered with various ... since have been discovered that also produce paclitaxel in other host species, ...
Ganguly A, Yang H, Cabral F (November 2010). "Paclitaxel-dependent cell lines reveal a novel drug activity". Molecular Cancer ... The drugs that can alter microtubule dynamics include: The cancer-fighting taxane class of drugs (paclitaxel (taxol) and ...
BMS manufactures paclitaxel using Penicillium and plant cell fermentation. Fungi can synthesize podophyllotoxin and ...
Paclitaxel (with albumin) Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving paclitaxel (with albumin) injection,. *tell your doctor and pharmacist if you are allergic to paclitaxel, ... If you or your partner become pregnant while receiving paclitaxel (with albumin) injection, call your doctor. Paclitaxel may ... Paclitaxel (with albumin) may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *pain ...
Paclitaxel total synthesis in organic chemistry is a major ongoing research effort in the total synthesis of paclitaxel (Taxol ... "Synthesis of Paclitaxel. 1. Synthesis of the ABC Ring of Paclitaxel by SmI2-Mediated Cyclization" Organic Letters 17 (11), 2570 ... but it also opens the way to paclitaxel derivatives not found in nature but with greater potential. The paclitaxel molecule ... Paclitaxel Total Syntheses @ SynArchive.com Taxolog for Taxol research, founded by Holto The complete Taxol story from Chemical ...
... has role human metabolite (CHEBI:77746) paclitaxel (CHEBI:45863) has role metabolite (CHEBI:25212) ... paclitaxel (CHEBI:45863) is a taxane diterpenoid (CHEBI:50367) paclitaxel (CHEBI:45863) is a tetracyclic diterpenoid (CHEBI: ... paclitaxel (CHEBI:45863) has functional parent baccatin III (CHEBI:32898) paclitaxel (CHEBI:45863) has role antineoplastic ... CHEBI:45863 - paclitaxel. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. .gridLayoutCellStructure { min- ...
A Case of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy without Exacerbation]. Gan to Kagaku Ryoho 44: 517-519, No. 6 ...
Paclitaxel, également connu sous le nom de Taxol, est un inhibiteur hydrophobe de mitotique avec un effet anticancéreux ... En 2005, approuvé par le FDA un paclitaxel de nanoparticle (également connu sous le nom dattrapent-paclitaxel) des biosciences ... Le paclitaxel semisynthétique Taxotere analogique dérivé de la substance de baccata de Taxus (un if européen) a été qualifié ... Paclitaxel est actuel des études pour dautres maladies qui exigent la stabilisation des microtubules et la manière déviter de ...
A list of US medications equivalent to Cipla-Paclitaxel is available on the Drugs.com website. ... Cipla-Paclitaxel is a medicine available in a number of countries worldwide. ... Ingredient matches for Cipla-Paclitaxel. Paclitaxel. Paclitaxel is reported as an ingredient of Cipla-Paclitaxel in the ... Cipla-Paclitaxel. Cipla-Paclitaxel may be available in the countries listed below. ...
Paclitaxel (taxol). Rowinsky EK1, Donehower RC.. Author information. 1. Division of Pharmacology and Experimental Therapeutics ...
Albumin-bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is ... Space-filling model of paclitaxel Rotating paclitaxel molecule model Crystal structure of paclitaxel Total charge surface of ... Moreover, Paclitaxel has been used in vitro to inhibit insulin fibrillation; in a molar ratio of 10:1 (insulin:paclitaxel), it ... Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle ...
paclitaxel (UNII: P88XT4IS4D) (paclitaxel - UNII:P88XT4IS4D) paclitaxel. 6 mg in 1 mL. ... p-hydroxy-paclitaxel and 6α, 3-p-dihydroxy-paclitaxel, by CYP3A4. In vitro, the metabolism of paclitaxel to 6α- ... Paclitaxel 135/3b q 3 wk (n=29). Study CA139-281 Paclitaxel 100/3b q 2 wk (n=56). ... Paclitaxel is obtained via an extraction process from Taxus X media Hicksii. The chemical name for paclitaxel is (2aR,4S,4aS, ...
Paclitaxel trevatide is a paclitaxel-Angiopep-2 conjugate. Various Angiopep vectors have been composed and differ by their anti ... Paclitaxel trevatide contains paclitaxel, which stabilizes microtubule polymer formation. Microtubules are composed of polymers ... Paclitaxel is generally prevented from reaching its target in the cell due to the presence of the efflux pump P-glycoprotein (P ... Paclitaxel trevatide has the potential to treat a variety of CNS diseases including glioma. Research has shown reduction in ...
FDA Investigating Late Risk With Paclitaxel Balloons, Stents in PAD * FDA Nixes, for Now, Lutonix Paclitaxel-Coated Balloon in ... It showed a 19% absolute risk reduction in TLR with the use of paclitaxel-coated devices, compared with noncoated devices, and ... A second review, published just days earlier, also showed no excess mortality risk with paclitaxel-coated stents and balloons ... Two new analyses provide conflicting evidence on the possible link between paclitaxel-coated devices and mortality raised by a ...
... are endowed with antitumor activity and show improved water solubility and decreased toxicity in comparison with paclitaxel or ... of units containing the paclitaxel and paclitaxel derivatives is from 0.5 to 2, more preferably, the content of paclitaxel in ... The paclitaxel content was 4% w/w%.. EXAMPLE 7. 2,7-di(carbobenzyloxy-β-alanyl)paclitaxel. To a solution of 200 mg of ... Water soluble paclitaxel prodrugs. US20080153865 *. Oct 29, 2007. Jun 26, 2008. Pg-Txl Company, L.P.. Water soluble paclitaxel ...
FDA Investigating Late Risk With Paclitaxel Balloons, Stents in PAD * Greater Risks With Post-TAVR Rivaroxaban Halt GALILEO ... PCR Stands Firm Behind Paclitaxel-Coated Devices in PAD * Peripheral Artery Disease in HIV-Infected Older Adults on ... It showed a 19% absolute risk reduction in TLR with the use of paclitaxel-coated devices, compared with noncoated devices, and ... A second review, published just days earlier, also showed no excess mortality risk with paclitaxel-coated stents and balloons ...
Paclitaxel is a taxoid chemotherapy drug originally extracted from the bark of the Pacific yew. It is sold under the trade name ... paclitaxel (thing). See all of paclitaxel, no other writeups in this node. ... Paclitaxel is a taxoid chemotherapy drug originally extracted from the bark of the Pacific yew. It is sold under the trade name ... Paclitaxel is given intravenously (it irritates skin and mucous membranes on contact), and is most effective against ovarian ...
Paclitaxel may lower your bodys resistance and the vaccine may not work as well or you might get the infection the vaccine is ... Paclitaxel can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. ... While you are being treated with paclitaxel, and after you stop treatment with it, do not have any immunizations (vaccines) ...
Paclitaxel is used to treat breast cancer, ovarian cancer, and lung cancer. It is also used to treat AIDS-related Kaposis ... Paclitaxel may also be used for purposes not listed in this medication guide. ... Paclitaxel is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... What is paclitaxel?. Paclitaxel is a cancer medication that interferes with the growth and spread of cancer cells in the body. ...
... & Docetaxel (Taxotere). [back] pharma drug list Trees Tree and Plant Abuse Herbs Yew ...
Paclitaxel (with polyoxyethylated castor oil) Injection: learn about side effects, dosage, special precautions, and more on ... If you become pregnant while receiving paclitaxel (with polyoxyethylated castor oil) injection, call your doctor. Paclitaxel ... When paclitaxel (with polyoxyethylated castor oil) is used to treat Kaposis sarcoma, it may be given once every 2 or 3 weeks. ... Paclitaxel injection is also sometimes used to treat cancer of the head and neck, esophagus (tube that connects the mouth and ...
Information about this paclitaxel-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Paclitaxel may lower your bodys resistance and the vaccine may not work as well or you might get the infection the vaccine is ... Paclitaxel injection is used to treat advanced cancer of the ovaries, breast, non-small cell lung cancer, and Kaposi sarcoma. ... Paclitaxel can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. ...
NANOPARTICLE ALBUMIN-BOUND PACLITAXEL (Na no PAHR ti kuhl al BYOO muhn-bound PAK li TAX el) is a chemotherapy drug. ... Nanoparticle Albumin-Bound Paclitaxel injection. What is this medicine?. NANOPARTICLE ALBUMIN-BOUND PACLITAXEL (Na no PAHR ti ... an unusual or allergic reaction to paclitaxel, albumin, other chemotherapy, other medicines, foods, dyes, or preservatives ...
... is used to treat cancer of the breast, lung, or pancreas. Paclitaxel protein-bound is sometimes given ... Paclitaxel protein-bound may also be used for... ... Paclitaxel protein-bound is a cancer medicine that interferes ... What is paclitaxel protein-bound?. Paclitaxel protein-bound is a cancer medicine that interferes with the growth and spread of ... How is paclitaxel protein-bound given?. Paclitaxel protein-bound is given as an infusion into a vein. A healthcare provider ...
Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Sylvie Rodrigues-Ferreira, Anne Nehlig, Hadia ... Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Sylvie Rodrigues-Ferreira, Anne Nehlig, Hadia ... Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy Message Subject (Your Name) has sent you a message ... Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Sylvie Rodrigues-Ferreira, Anne Nehlig, Hadia ...
... model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and... ... Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with ... Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 23(6):1243- ... Zhang W, Shi Y, Chen Y, Yu S, Hao J, Luo J, Sha X, Fang X (2010) Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123 ...
Plasma concentration-time curves of paclitaxel after paclitaxel administration (10 mg/kg) pretreated with nilotinib (100 mg/kg ... Paclitaxel is among the most widely used anticancer drugs and is known to cause a dose-limiting peripheral neurotoxicity, the ... Here, we identified the murine solute carrier organic anion-transporting polypeptide B2 (OATP1B2) as a mediator of paclitaxel- ... Additionally, using established tests to assess acute and chronic paclitaxel-induced neurotoxicity, we found that genetic or ...
Paclitaxel (Protein Bound) - Last updated on March 6, 2021. All rights owned and reserved by Memorial Sloan Kettering Cancer ...
The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with ... 3. To measure the plasma pharmacokinetics of LOC-paclitaxel and paclitaxel derived from LOC-paclitaxel in patients receiving ... The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with ... Part I 1. To determine the recommended dose of LOC-paclitaxel as a single agent, given weekly, 5/6 weeks. 2. To determine the ...
Paclitaxel is among the most widely used anticancer drugs and is known to cause a dose-limiting peripheral neurotoxicity, the ... Here, we identified the murine solute carrier organic anion-transporting polypeptide B2 (OATP1B2) as a mediator of paclitaxel- ... Additionally, using established tests to assess acute and chronic paclitaxel-induced neurotoxicity, we found that genetic or ... Collectively, our findings reveal a pathway that explains the fundamental basis of paclitaxel-induced neurotoxicity, with ...
... paclitaxel) as part of my chemo. Both Taxol and its cousin Taxotere (docetaxel) need to be dissolved in a solvent before they ... Abraxane (nab-paclitaxel) is the same active ingredient as Taxol, but scientists have found a new way to deliver it. The nab ... Like many other people, I had Taxol (paclitaxel) as part of my chemo. Both Taxol and its cousin Taxotere (docetaxel) need to be ... to mix the paclitaxel has proved to be a safe and less toxic way to deliver the drug. ...
Si es alérgico al paclitaxel o cualquier otro componente de este medicamento. ...
This page contains brief information about paclitaxel albumin-stabilized nanoparticle formulation and a collection of links to ... Paclitaxel albumin-stabilized nanoparticle formulation is a form of paclitaxel contained in nanoparticles (very tiny particles ... This form may work better than other forms of paclitaxel and have fewer side effects. For more information about paclitaxel ... Paclitaxel albumin-stabilized nanoparticle formulation is approved to be used alone or with other drugs to treat:. *Breast ...
  • Paclitaxel total synthesis in organic chemistry is a major ongoing research effort in the total synthesis of paclitaxel (Taxol). (wikipedia.org)
  • Paclitaxel, également connu sous le nom de Taxol, est un inhibiteur hydrophobe de mitotique avec un effet anticancéreux puissant. (news-medical.net)
  • Sur l'approbation des USA Food and Drug Administration (FDA), en 1992 Bristol-Myers Squibb a lancé le médicament comme Taxol. (news-medical.net)
  • Paclitaxel (PTX), sold under the brand name Taxol among others, is a chemotherapy medication used to treat a number of types of cancer. (wikipedia.org)
  • Paclitaxel (also named Taxol in several publications) is a member of the taxane family of diterpenes, isolated and characterized from an extract of bark of Taxus brevifolia L. (google.com)
  • Like many other people, I had Taxol (paclitaxel) as part of my chemo. (healthcentral.com)
  • Abraxane (nab-paclitaxel) is the same active ingredient as Taxol, but scientists have found a new way to deliver it. (healthcentral.com)
  • Cordes, N. and Plasswilm, L. (1998) Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): Role of the solvent Cremophor EL/ethanol. (scirp.org)
  • Feng, S. and Huang, G. (2001) Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. (scirp.org)
  • Taxol is the brand name of paclitaxel, but the patent expired, meaning the medicine is available as a generic. (breastcancer.org)
  • Recently, we reported preliminary data on our experience with sequentialdoxorubicin (Adriamycin) followed by paclitaxel (Taxol) in the treatmentof advanced breast cancer that was either untreated or had relapsed afteradjuvant therapy. (cancernetwork.com)
  • Six months surgery, 37 percent of the people who did not get Taxol and 29 percent of those who got their paclitaxel in the contrast medium needed to have their arteries reopened compared to only 4 percent of those who got the drug via the coated balloon. (china.org.cn)
  • Paclitaxel (taxol) is an important agent against many tumors, including breast cancer. (bioportfolio.com)
  • SAN ANTONIO-A weekly outpatient paclitaxel (Taxol) regimen led to rapid responses in more than 40% of a group of heavily pretreated women with metastatic breast cancer, said Dr. Hans-Joachim Luck, of the Medical University of Hannover, Germany. (cancernetwork.com)
  • PHILADELPHIA - Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania. (eurekalert.org)
  • We have determined the in vitro and in vivo cellular distribution of the antineoplastic agent paclitaxel (Taxol) in human blood and the influence of Cremophor EL (CrEL), the vehicle used for i.v. drug administration. (aacrjournals.org)
  • Paclitaxel (with albumin) injection is also used in combination with other chemotherapy medications to treat non-small cell lung cancer (NSCLC). (medlineplus.gov)
  • In September 2001, NICE recommended paclitaxel should be available for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. (wikipedia.org)
  • Paclitaxel trevatide (development codes NG1005 and GRN1005) is an experimental chemotherapy drug that is under development by Angiochem Inc, a Canadian biotech company. (wikipedia.org)
  • Paclitaxel is a taxoid chemotherapy drug originally extracted from the bark of the Pacific yew . (everything2.com)
  • Paclitaxel (with polyoxyethylated castor oil) injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
  • Paclitaxel (with polyoxyethylated castor oil) is used along or along with other chemotherapy medications to treat breast cancer, ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), and non-small cell lung cancer (NSCLC). (medlineplus.gov)
  • Paclitaxel (protein bound) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. (chemocare.com)
  • Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. (tradeindia.com)
  • The study hypothesizes that the addition of intraperitoneal paclitaxel with chemotherapy will improve treatment efficacy. (clinicaltrials.gov)
  • In patients with histologically proven unresectable or recurrent gastric cancer limited to the peritoneum and/or cancer cells in peritoneal cytology, the combination of i.p. paclitaxel with systemic chemotherapy reported a median survival time of 23.6 months. (clinicaltrials.gov)
  • A phase III trial (PHOENIX-GC trial (Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis )) comparing intraperitoneal(IP) regimen with systemic chemotherapy versus systemic therapy alone is currently opened for recruitment in Japan. (clinicaltrials.gov)
  • This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. (cancer.gov)
  • Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (cancer.gov)
  • Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment. (cancer.gov)
  • Women diagnosed with metastatic breast cancer who were treated with an oral form of the chemotherapy medicine called paclitaxel seemed to have a better response to treatment and less neuropathy compared to women treated with the IV version of paclitaxel, according to a study. (breastcancer.org)
  • Paclitaxel is a type of chemotherapy called a taxane. (breastcancer.org)
  • Paclitaxel is usually given in combination with other chemotherapy medicines intravenously, which means the medicine is delivered directly into your bloodstream through an IV or a port. (breastcancer.org)
  • Chemotherapy medicines, such as paclitaxel, travel throughout the body, where they can cause damage to the nerves. (breastcancer.org)
  • For the adjuvant treatment of node-positive breast cancer, the recommended regimen is paclitaxel, at a dose of 175 mg/m2 intravenously over 3 hours every 3 weeks for four courses administered sequentially to doxorubicin-containing combination chemotherapy. (fresenius-kabi.com)
  • After failure of initial chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, paclitaxel at a dose of 175 mg/m2 administered intravenously over 3 hours every 3 weeks has been shown to be effective. (fresenius-kabi.com)
  • Paclitaxel Injection (INTAXEL) is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. (fresenius-kabi.com)
  • Paclitaxel Injection (INTAXEL) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. (fresenius-kabi.com)
  • In this updated analysis of weekly chemotherapy in patients with chemotherapy-naive metastatic breast cancer, ixabepilone continued to be inferior to paclitaxel for PFS," Rugo concluded. (healio.com)
  • It also showed that adding trastuzumab to sequential paclitaxel and FEC chemotherapy significantly increased pCR (25% vs 66.7%) in preoperative setting for HER2 positive disease. (bioportfolio.com)
  • We will examine the hypothesis that paclitaxel, gemcitabine, and lapatinib (Tykerb®) (PGT) combination could improve the pathological complete response rate of HER2 positive breast cancer when applied as a preoperative chemotherapy. (bioportfolio.com)
  • So we designed this phase I/II study to evaluate the efficacy and toxicity of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine and platinum-pretreated advanced gastric cancer. (knowcancer.com)
  • This trial looked at 2 drugs called trametinib and pazopanib with paclitaxel chemotherapy in melanoma skin cancer. (cancerresearchuk.org)
  • Paclitaxel chemotherapy is a possible treatment for melanoma skin cancer that has spread. (cancerresearchuk.org)
  • Doctors thought that adding trametinib or pazopanib to paclitaxel chemotherapy might work better than paclitaxel only. (cancerresearchuk.org)
  • The main aim of this trial was to find out if trametinib or pazopanib with paclitaxel chemotherapy improved treatment. (cancerresearchuk.org)
  • Paclitaxel (with albumin) injection may cause a large decrease in the number of white blood cells (a type of blood cell that is needed to fight infection) in your blood. (medlineplus.gov)
  • or other signs of infection during your treatment with paclitaxel injection. (medlineplus.gov)
  • Your doctor will order certain tests to check your body's response to paclitaxel (with albumin) injection. (medlineplus.gov)
  • Talk to your doctor about the risks of receiving paclitaxel (with albumin) injection. (medlineplus.gov)
  • Paclitaxel (with albumin) injection is used to treat breast cancer that has spread to other parts of the body and has not improved or worsened after treatment with other medications. (medlineplus.gov)
  • Paclitaxel (with albumin) injection is used in combination with gemcitabine (Gemzar) to treat cancer of the pancreas. (medlineplus.gov)
  • Paclitaxel (with albumin) injection comes as a powder to be mixed with liquid to be injected over 30 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • When paclitaxel (with albumin) injection is used to treat breast cancer, it is usually given once every 3 weeks. (medlineplus.gov)
  • When paclitaxel (with albumin) injection is used to treat non-small cell lung cancer it is usually given on days 1, 8, and 15 as part of a 3 week cycle. (medlineplus.gov)
  • Paclitaxel injection is also sometimes used to treat cancer of the head and neck, esophagus (tube that connects the mouth and stomach), bladder, endometrium (lining of the uterus), and cervix (opening of the uterus). (medlineplus.gov)
  • Paclitaxel Injection, USP should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. (nih.gov)
  • Paclitaxel Injection, USP is a clear colorless to slightly yellow viscous solution. (nih.gov)
  • Call your doctor for instructions if you miss an appointment for your paclitaxel injection. (cigna.com)
  • Paclitaxel (with polyoxyethylated castor oil) injection may cause serious or life-threatening allergic reactions. (medlineplus.gov)
  • Paclitaxel (with polyoxyethylated castor oil) injection is also used to treat Kaposi's sarcoma (a type of cancer that causes patches of abnormal tissue to grow under the skin) in people who have acquired immunodeficiency syndrome (AIDS). (medlineplus.gov)
  • Paclitaxel (with polyoxyethylated castor oil) injection comes as a liquid to be injected over 3 or 24 hours intravenously by a doctor or nurse in a hospital or clinic. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to paclitaxel, docetaxel, any other medications, polyoxyethylated castor oil (Cremophor EL), or medications that contain polyoxyethylated castor oil such as cyclosporine injection (Sandimmune) or teniposide (Vumon). (medlineplus.gov)
  • Paclitaxel injection is used to treat advanced cancer of the ovaries, breast, non-small cell lung cancer, and Kaposi sarcoma. (mayoclinic.org)
  • Appropriate studies have not been performed on the relationship of age to the effects of paclitaxel injection in the pediatric population. (mayoclinic.org)
  • Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of paclitaxel injection in the elderly. (mayoclinic.org)
  • However, elderly patients are more likely to have unwanted side effects (e.g., heart disease, bone marrow problems, and nerve problems), which may require caution in patients receiving paclitaxel injection. (mayoclinic.org)
  • Paclitaxel (protein bound) is administered into a vein by intravenous (IV) injection through a central line or a peripheral venous line. (chemocare.com)
  • Paclitaxel is given as an injection or infusion into the vein (intravenous, IV). (chemocare.com)
  • Paclitaxel Injection (INTAXEL) is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. (fresenius-kabi.com)
  • As first-line therapy, Paclitaxel Injection is indicated in combination with cisplatin. (fresenius-kabi.com)
  • Paclitaxel Injection (INTAXEL) in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. (fresenius-kabi.com)
  • Paclitaxel Injection (INTAXEL) is indicated for the second-line treatment of AIDS- related Kaposi's sarcoma. (fresenius-kabi.com)
  • Paclitaxel Injection (Intaxel) is available as 30 mg/5ml, 100 mg/17ml and 260 mg/43.4 ml vials individually packaged in a carton. (fresenius-kabi.com)
  • A formulation for preparing Paclitaxel 6-mg/mL Injection. (ijpc.com)
  • Deals in paclitaxel injections, Docetaxel Injection (Sibatere 80MG), Oxaliplatin Injection (Sibatin 50MG), Gemcitabine Injection (Sibagem 1GM), Docetaxel Injection (Sibatere 120MG), Gemcitabine Injection (Sibagem 200MG), Oxaliplatin Injection (Sibatin 100MG), Docetaxel Injection (Sibatere 20MG). (indianyellowpages.com)
  • Drinking alcohol can increase certain side effects of paclitaxel. (cigna.com)
  • What are the possible side effects of paclitaxel? (cigna.com)
  • There are many options to minimize or prevent the side effects of paclitaxel (protein bound). (chemocare.com)
  • The side effects of Paclitaxel and their severity vary depending on how much of the drug is given, and/or the schedule in which it is given. (chemocare.com)
  • Neurotoxicity is one of the most prominent side effects of paclitaxel. (diva-portal.org)
  • The study concluded that resveratrol improved the anticancer effects of paclitaxel on human liver cancer cells, allowing reduced amounts of the cancer-fighting substance to be used in treatments. (naturalnews.com)
  • Given resveratrol's demonstrated ability to improve the cancer-fighting effects of paclitaxel, the researchers came to the conclusion that the former could serve as a sensitizing agent for the latter. (naturalnews.com)
  • Given the results of their experiment, the CSU researchers concluded that resveratrol could be used as a sensitizing agent that improved the anticancer effects of paclitaxel on human liver cancer cells. (naturalnews.com)
  • En 2005, approuvé par le FDA un paclitaxel de nanoparticle (également connu sous le nom d'attrapent-paclitaxel) des biosciences d'Abraxis sous un nom Abraxane. (news-medical.net)
  • Albumin-bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nanoparticles. (wikipedia.org)
  • Abraxis BioScience developed Abraxane, in which paclitaxel is bonded to albumin as an alternative delivery agent to the often toxic solvent delivery method. (wikipedia.org)
  • Abraxane: A Better Delivery System for Paclitaxel? (healthcentral.com)
  • In some cases, health care professionals may use the trade name Abraxane® when referring to the generic drug name paclitaxel (protein bound). (chemocare.com)
  • However, a large international trial showed that combining gemcitabine with a drug called nab-paclitaxel (or abraxane) was more effective compared with gemcitabine alone. (clinicaltrials.gov)
  • This compound is a biosynthetic precursor and is found in larger quantities than paclitaxel itself in Taxus baccata (the European Yew). (wikipedia.org)
  • Le paclitaxel semisynthétique Taxotere analogique dérivé de la substance de baccata de Taxus (un if européen) a été qualifié par Sanofi Aventis. (news-medical.net)
  • Paclitaxel drug-eluting stents for coronary artery placement are sold under the trade name Taxus by Boston Scientific in the United States. (wikipedia.org)
  • other analogues of paclitaxel are also known and were prepared by semisynthesis starting from 10-deacetyl baccatin III, extracted from the needles of Taxus baccata L., see Wain et al. (google.com)
  • Paclitaxel is a diterpene alkaloid originally isolated from the bark of the Pacific Yew tree (Taxus brevifolia). (stemcell.com)
  • The five-year meta-analysis of approximately 2,800 patients in our TAXUS clinical trials demonstrated no difference in long-term mortality with the paclitaxel-eluting TAXUS coronary stent compared to bare metal stents. (bostonscientific.com)
  • Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. (bostonscientific.com)
  • Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberte paclitaxel-eluting stent in de-novo coronary artery lesions. (bostonscientific.com)
  • Paclitaxel is a microtubule-stabilizing agent originally isolated from the bark of Taxus brevifolia. (spandidos-publications.com)
  • To prevent this, Cardiologists at Elliot use a TAXUS™ Express²™ Paclitaxel-Eluting Coronary Stent System. (elliothospital.org)
  • More information on the TAXUS™ Express²™ Paclitaxel-Eluting Coronary Stent System can be found at www.BostonScientific.com . (elliothospital.org)
  • Paclitaxel is derived from the Pacific yew ( Taxus brevifolia ), a conifer tree native to the Pacific Northwest. (naturalnews.com)
  • Paclitaxel, originally isolated from Taxus brevifolia (pacific yew), is one of the most active chemotherapeutic agents against a wide panel of solid tumors including urothelial, breast, lung, and ovarian cancers ( 1 , 2 ). (aacrjournals.org)
  • Increased paclitaxel-induced cytotoxicity of BAX clones was associated with enhanced apoptosis, as assessed by morphologic and flow cytometric criteria. (pnas.org)
  • Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. (stemcell.com)
  • PURPOSE: The molecular signal components essential to paclitaxel-dependent apoptosis in breast cancers are potential targets for combined therapy. (stemcell.com)
  • EXPERIMENTAL DESIGN: In a breast cancer cell line, pharmacological agents and transient transfection with dominant interfering and constitutive active mutants were used to identify the signal transduction module involved in the regulation of paclitaxel-induced apoptosis and to evaluate its potential as a therapeutic target. (stemcell.com)
  • RESULTS: In MDA-MB-435 cells, paclitaxel treatment stimulated the activity of both protein kinase A and p38, and inhibited the activity of the Na(+)/H(+) exchanger isoform 1 (NHE1) with similar IC(50) concentrations as for its activation of apoptosis. (stemcell.com)
  • Importantly, concurrent specific inhibition of the NHE1 with paclitaxel treatment resulted in a synergistic induction of apoptosis and a reduction in the paclitaxel IC(50) for apoptosis. (stemcell.com)
  • CONCLUSIONS: We have, for the first time, identified NHE1 as an essential component of paclitaxel-induced apoptosis in breast cancer cells and, importantly, identified that simultaneous inhibition of the NHE1 results in a synergistic potentiation of low-dose paclitaxel apoptotic action. (stemcell.com)
  • Paclitaxel also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (drugbank.ca)
  • Furthermore, the combination of resveratrol and paclitaxel-H was able to cause the most apoptosis in HepG2 cells. (naturalnews.com)
  • Additional treatment with resveratrol raised the number of liver cancer cells that underwent apoptosis for both paclitaxel concentrations. (naturalnews.com)
  • As with the majority of anticancer agents, paclitaxel causes cancer cell death with signs of apoptosis and also it is supposedly associated with mitotic catastrophe ( 8 , 9 ). (spandidos-publications.com)
  • Paclitaxel-induced apoptosis in hepatoma cells is mediated through G 2 -M arrest and DNA fragmentation ( 5 ). (aacrjournals.org)
  • However, the observation that in some cell lines, pulsed paclitaxel exposures causes apoptosis but not G 2 -M arrest suggests that paclitaxel-induced apoptosis may occur without a prior G 2 -M arrest ( 9 ). (aacrjournals.org)
  • Moreover, paclitaxel has been shown to induce apoptosis in G 1 and S stages, but induce both apoptosis and necrosis in G 2 -M phase ( 10 ). (aacrjournals.org)
  • Moreover, treatment of the human T-cell lymphoblastic leukemia cell line CCRF-HSB-2 with the antioxidant N -acetyl- l -cysteine showed inhibition of paclitaxel-induced ROS production but did not prevent paclitaxel-induced apoptosis, indicating that paclitaxel-induced apoptosis in these cells is ROS independent ( 13 ). (aacrjournals.org)
  • Results support our hypothesis that ROS and reactive nitrogen species are involved in paclitaxel-induced apoptosis. (aacrjournals.org)
  • Immunoblotting revealed that BAX transfectants expressed a mean of 10-fold increased levels of BAX compared with neo-transfected control clones, with similar levels of BCL-2 and BCL-x L . The cytotoxicity of paclitaxel, vincristine, and doxorubicin was significantly enhanced in BAX transfectants compared with control clones, whereas the cytotoxicity profile of carboplatin, etoposide, and hydroxyurea was unchanged. (pnas.org)
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. (nih.gov)
  • The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. (nih.gov)
  • The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group. (nih.gov)
  • Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. (nih.gov)
  • The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. (mdanderson.org)
  • To evaluate objective response rate of patients with metastatic uveal melanoma to Genasense-Carboplatin-Paclitaxel (GCP) combination Secondary objectives: a. (mdanderson.org)
  • Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery. (wikipedia.org)
  • Docetaxel has a similar set of clinical uses to paclitaxel, and it is marketed under the brand name Taxotere. (wikipedia.org)
  • Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2% to 4% of patients receiving paclitaxel in clinical trials. (nih.gov)
  • Slightly less than half of the patients receiving paclitaxel during clinical trials developed an allergic reaction to it, which resulted in problems ranging from rashes or a mild drop in blood pressure to major breathing problems, hives and/or fluid buildup around the heart. (everything2.com)
  • The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. (mdanderson.org)
  • This page contains brief information about paclitaxel albumin-stabilized nanoparticle formulation and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. (cancer.gov)
  • Find Clinical Trials for Paclitaxel Albumin-stabilized Nanoparticle Formulation - Check for trials from NCI's list of cancer clinical trials now accepting patients. (cancer.gov)
  • The clinical trials on this list are studying Paclitaxel Albumin-Stabilized Nanoparticle Formulation. (cancer.gov)
  • ABSTRACT: Based on preclinical data, we designeda phase I/II clinical trial to determine the efficacy and toxicity of doxorubicinfollowed by paclitaxel in the treatment of advanced breast cancer (eitheruntreated or relapsed after adjuvant therapy). (cancernetwork.com)
  • This effect was confirmed in 11 cultures of human breast cancer (synergisticand additive effects were observed in four and six cases, respectively).On the basis of these preclinical data, we designed a clinical trial toevaluate the efficacy of a sequential regimen in which doxorubicin wasfollowed by paclitaxel. (cancernetwork.com)
  • SAN ANTONIO - Ixabepilone appeared inferior to paclitaxel and nab-paclitaxel in terms of OS among patients with locally recurrent or metastatic breast cancer, according to long-term follow-up of a phase 3 clinical trial presented at the San Antonio Breast Cancer Symposium. (healio.com)
  • The clinical trial, sponsored by Celgene Corporation, involved 861 patients, half of whom were administered the nab-paclitaxel/gemcitabine combination, while the other half received gemcitabine alone. (eurekalert.org)
  • A phase II study with preoperative paclitaxel and gemcitabine in stage II/III showed 18 % pCR rate at NCC (ASCO 2007 abstract #11080) In HER2 positive breast cancer, HER2 targeted therapies with trastuzumab and lapatinib have shown much improved clinical response in palliative setting. (bioportfolio.com)
  • The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patient. (bioportfolio.com)
  • The findings confirm previous evidence of high activity with weekly paclitaxel in heavily pretreated patients presented last year at the American Society of Clinical Oncology meeting (Proc Am Soc Clin Oncol 16:597, 1997), he added. (cancernetwork.com)
  • The response rates are at least comparable to those observed in early paclitaxel clinical trials in similar populations of heavily pretreated breast cancer patients, he added. (cancernetwork.com)
  • We are confident in the safety and clinical benefits of our Eluvia™ Drug-Eluting Vascular Stent (DES) System and continue to provide the U.S. Food and Drug Administration (FDA) with clinical data about our Eluvia stent and related paclitaxel-polymer technologies to support the use of these devices to treat peripheral artery disease (PAD). (bostonscientific.com)
  • We will continue our collection of long-term clinical data through follow-up of the nearly 2,000 patients enrolled in our global trials of Eluvia, as well as our robust, post-market surveillance process, and our stringent documentation of adverse events, all of which will add to the Boston Scientific body of clinical evidence supporting our paclitaxel-eluting devices to ensure that patients have access to safe and effective treatment options. (bostonscientific.com)
  • That seemed better than what we would have expected from paclitaxel alone, but the only way to know the difference for certain is with a randomized clinical trial of the combination versus the single drug," DeMichele said. (eurekalert.org)
  • The combination was considered safe at the full recommended tivozanib dose (1.5 mg/day) and standard paclitaxel dose, and demonstrated encouraging clinical activity in patients with metastatic breast cancer. (news-medical.net)
  • These results suggest that paclitaxel chemosensitivity may be predicted by taking total antioxidant capacity measurements from clinical tumor samples. (aacrjournals.org)
  • Bi-weekly administration of paclitaxel and cisplatin in patients with advanced esophageal cancer results in amedian survival for all patients of 9 months. (greenmedinfo.com)
  • For patients with non-small cell lung carcinoma, the recommended regimen, given every 3 weeks, is paclitaxel administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin, 75 mg/m2. (fresenius-kabi.com)
  • The IC50 values of WOG, cisplatin (CDDP) and paclitaxel (PTX) in four gastric cancer cell lines were determined by MTS assay. (greenmedinfo.com)
  • The compounds are endowed with antitumor activity and show improved water solubility and decreased toxicity in comparison with paclitaxel or its known analogs. (google.com)
  • More particularly the present invention provides polymer conjugates of paclitaxel and derivatives of paclitaxel with improved water solubility and decreased toxicity. (google.com)
  • 2. To determine the qualitative and quantitative toxicity and reversibility of toxicity of weekly LOC-paclitaxel. (mdanderson.org)
  • A phase I study combining i.p. paclitaxel with oxaliplatin and S-1, found no dose limiting toxicity in all dose levels. (clinicaltrials.gov)
  • DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when compared to conventional paclitaxel and has demonstrated antineoplastic activity in animal models of cancer. (drugbank.ca)
  • Purpose: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. (diva-portal.org)
  • Paclitaxel (1a), a well known antitumor agent adopted mainly for the treatmentof breast and ovarian cancer, suffers from significant disadvantages such as low solubility,certain toxicity and specific drug-resistance of some tumor cells. (mdpi.com)
  • Researchers have been looking for ways to improve the absorption and effectiveness of paclitaxel while also reducing its toxicity. (naturalnews.com)
  • The current study reveals our investigation into the role(s) of ROS and reactive nitrogen species in paclitaxel toxicity. (aacrjournals.org)
  • In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. (wikipedia.org)
  • In 2014, paclitaxel trevatide received orphan drug designation from FDA for the treatment of glioblastoma multiform As of January 2016, Angiochem has conducted phase II trials for the treatment of breast cancer with brain metastasis, glioblastoma, and high-grade glioma. (wikipedia.org)
  • Paclitaxel is given intravenously (it irritates skin and mucous membrane s on contact), and is most effective against ovarian cancer s ( carcinoma s) and advanced breast cancer s. (everything2.com)
  • Paclitaxel is used to treat breast cancer, ovarian cancer, and lung cancer. (cigna.com)
  • When paclitaxel (with polyoxyethylated castor oil) is used to treat breast cancer, ovarian cancer, or non-small cell lung cancer it is usually given once every 3 weeks. (medlineplus.gov)
  • This sensitization of paclitaxel apoptotic action by specific inhibition of NHE1 was verified in breast cancer cell lines with different paclitaxel sensitivity. (stemcell.com)
  • Curcumin works synergistically with paclitaxel to inhibit breast cancer cell metastasis to the lung in a mouse model. (greenmedinfo.com)
  • EGCG sensitizes breast cancer cells to paclitaxel in a mouse model of breast carcinoma. (greenmedinfo.com)
  • Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer? (breastcancer.org)
  • Paclitaxel is a mitotic inhibitor that is FDA approved for the treatment of metastatic breast cancer , non-small cell lung cancer and adenocarcinoma of the pancreas . (wikidoc.org)
  • Interesting phase 3 trial for metastatic breast cancer using a modified oral paclitaxel compared to standard IV paclitaxel every 3 weeks, which found both better response and less neuropathy. (cancer.org)
  • Paclitaxel is a antimicrotubule agent with established antitumour activity in a variety of cancers including breast cancer. (nih.gov)
  • In randomised trials of neoadjuvant therapy for women with early breast cancer, paclitaxel or paclitaxel-containing regimens showed efficacy in terms of response/remission rates, local breast tumour recurrence and proportion of patients eligible for breast-conserving surgery. (nih.gov)
  • In the phase I study, patients with advanced breast cancer were treatedwith a fixed dose of doxorubicin (50 mg/m²) by intravenous bolus,16 hours before receiving a three-hour infusion of paclitaxel (in escalatingdoses from 130 mg/m² to 250 mg/m²). (cancernetwork.com)
  • The goals of the study were to definethe maximum tolerated dose (MTD) of paclitaxel given in combination withfixed-dose doxorubicin in treating patients with breast cancer that hadrelapsed after adjuvant therapy or had not been treated previously withchemotherapy, and to evaluate the efficacy and tolerability of a short(three hours) paclitaxel infusion. (cancernetwork.com)
  • Researchers evaluated weekly paclitaxel 90 mg/m 2 compared with weekly nab-paclitaxel 150 mg/m 2 or weekly ixabepilone 16 mg/m 2 with or without 10 mg/kg bevacizumab (Avastin, Genentech) every 2 weeks as first-line therapy for locally recurrent or metastatic breast cancer. (healio.com)
  • Paclitaxel has been shown to be an effective agent in the treatment of breast cancer. (bioportfolio.com)
  • Paclitaxel plus gemcitabine combination showed overall survival benefit compared to paclitaxel alone in patients with metastatic breast cancer in an interim overall survival report. (bioportfolio.com)
  • This study investigates the safety and efficacy of oral lapatinib in combination with an approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer. (bioportfolio.com)
  • Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signaling pathway. (bioportfolio.com)
  • Ample data documents that paclitaxel inhibits breast cancer metastasis while others prove that paclitaxel enhance. (bioportfolio.com)
  • These results show that a weekly paclitaxel schedule is feasible in the outpatient setting and leads to a substantial response rate in heavily pretreated patients, Dr. Luck said at a poster presentation at the 20th Annual San Antonio Breast Cancer Symposium. (cancernetwork.com)
  • The breast cancer treatments (paclitaxel and Trastuzumab) used in this study are considered part of standard-of-care regimens in early breast cancer. (mayo.edu)
  • In this research study, the investigators are looking to see if the study drug T-DM1 will have less side effects than traditional HER2-positive breast cancer treatment of trastuzumab and paclitaxel. (mayo.edu)
  • Results of the first study found that palbociclib and paclitaxel can be safely combined on an alternating dosing schedule," said Angela DeMichele, MD, MSCE, the Alan and Jill Miller Associate Professor in Breast Cancer Excellence in Penn's Abramson Cancer Center, and senior author on the study. (eurekalert.org)
  • To begin to test this concept in the clinic, DeMichele and colleagues, including lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology-Oncology in the Abramson Cancer Center, treated 27 breast cancer patients with alternating doses of palbociclib - administered daily for several days at a time - and paclitaxel administered once per week. (eurekalert.org)
  • Further study of tivozanib in combination with anti-cancer agents such as paclitaxel is warranted in breast cancer. (news-medical.net)
  • The Phase 1b open-label, dose-escalation study assessed once-daily, oral tivozanib (sequential cohorts of 0.5, 1.0, and 1.5 mg/day for three weeks on, one week off) and paclitaxel (once-weekly intravenously for three weeks on, one week off) in 18 patients with metastatic breast cancer, all of whom had prior taxane therapy and most of whom had prior bevacizumab therapy. (news-medical.net)
  • Curcumin and paclitaxel were evaluated with two human breast cancer cell lines as the luminal MCF-7 and the basal-like MDA-MB-231 that are either positive or negative for hormonal receptors estrogen receptor, progesterone receptor and HER2, respectively. (spandidos-publications.com)
  • The German research presented at The 27 th Annual Breast Cancer Symposium in San Antonio, by researchers from the Fredrich Schiller University showed that Paclitaxel caused the greatest shrinkage of a breast cancer tumour but a simultaneous release of the greatest number of circulating cancer cells as the tumour broke down. (canceractive.com)
  • Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis. (sigmaaldrich.com)
  • Bien que la liste de cancers visés par le paclitaxel augmente toujours, son rôle principal est jusqu'à présent en traitant le carcinome métastatique de l'ovaire, non-petit carcinome de poumon de cellules, cancer du sein métastatique et comme agent de deuxième-line dans le sarcome lié au SIDA de Kaposi. (news-medical.net)
  • Paclitaxel trevatide will cross the capillary medium via receptor mediated transcytosis of the low-density lipoprotein receptor-related protein 1 (LRP1) which is upregulated in some cancers. (wikipedia.org)
  • The researchers who did the study looked to see how the cancers responded to the two forms of paclitaxel. (breastcancer.org)
  • Overall, 35.8% of the cancers treated with oral paclitaxel responded to the treatment compared to 23.4% of cancers treated with IV paclitaxel. (breastcancer.org)
  • This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). (mayo.edu)
  • Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer. (mayo.edu)
  • Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in a biphasic manner. (nih.gov)
  • Paclitaxel empêche la ségrégation de division cellulaire et de chromosome en visant le tubulin et en stabilisant des microtubules. (news-medical.net)
  • Paclitaxel est actuel des études pour d'autres maladies qui exigent la stabilisation des microtubules et la manière d'éviter de l'angiogenèse et de la prolifération cellulaire. (news-medical.net)
  • Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. (nih.gov)
  • In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. (nih.gov)
  • Paclitaxel, a potent disruptor of microtubules derived from the bark of the Pacific yew tree, is widely used as a chemotherapeutic compound. (tradeindia.com)
  • Because tumor cells take up DHA, DHA-paclitaxel is delivered directly to tumor tissue, where the paclitaxel moiety binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. (drugbank.ca)
  • Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. (sigmaaldrich.com)
  • Paclitaxel promotes the stable assembly of microtubules from α- and β-tubulin heterodimers and inhibits their de-polymerization ( 3 ). (aacrjournals.org)
  • Dr Ahmed Ashour Ahmed, Cancer Research UK clinician scientist, and first author of the paper, said: "Our work reveals that some proteins that surround cancer cells such as TGFBI send messages to microtubules, the backbone of the cell, sensitising them to paclitaxel. (ecancer.org)
  • Paclitaxel is one of several cytoskeletal drugs that target tubulin. (wikipedia.org)
  • Therefore, paclitaxel binds at the site of β-tubulin and induces polymerization, thus protecting the microtubule from disassembling during mitosis. (wikipedia.org)
  • This results in the intracellular release of paclitaxel and subsequent action on tubulin. (wikipedia.org)
  • Paclitaxel is a highly active antitumor agent that promotes microtubule assembly by binding to tubulin and inhibiting depolymerization. (bioportfolio.com)
  • In this Phase 1 study, the combination of tivozanib and weekly paclitaxel was tolerable for patients and demonstrated notable activity,' said Dr. Mayer. (news-medical.net)
  • You should not receive paclitaxel (with albumin) if you already have a low number of white blood cells. (medlineplus.gov)
  • Do not receive paclitaxel if you are pregnant. (cigna.com)
  • Another 54 people did not receive paclitaxel in any form. (china.org.cn)
  • Paclitaxel albumin-stabilized nanoparticle formulation is a form of paclitaxel contained in nanoparticles (very tiny particles of protein ). (cancer.gov)
  • This guidance replaces NICE technology appraisal guidance 360 on paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer. (nice.org.uk)
  • NICE reviewed its technology appraisal guidance on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360) because the company submitted more evidence and proposed a patient access scheme that would make nab‑paclitaxel available with a confidential price discount. (nice.org.uk)
  • Paclitaxel will be administered intraperitoneally at 40mg/m2 on Day 1 and 8 in patients receiving standard intravenous oxaliplatin 130mg/m2 on Day 1 and capecitabine 1000mg/m2 on day 1-14. (clinicaltrials.gov)
  • To allow the medicine to enter the bloodstream, intravenous paclitaxel is mixed with solvents. (breastcancer.org)
  • The pharmacokinetics of paclitaxel were also evaluated in adult cancer patients who received single doses of 15 to 135 mg/m 2 given by 1-hour infusions (n=15), 30 to 275 mg/m 2 given by 6-hour infusions (n=36), and 200 to 275 mg/m 2 given by 24-hour infusions (n=54) in Phase 1 & 2 studies. (nih.gov)
  • 3. To measure the plasma pharmacokinetics of LOC-paclitaxel and paclitaxel derived from LOC-paclitaxel in patients receiving escalating doses of weekly LOC-paclitaxel. (mdanderson.org)
  • Different doses of paclitaxel and its combination with resveratrol were tested on cultured normal cells and HepG2 liver cancer cells. (naturalnews.com)
  • Several groups received different doses of Paclitaxel. (naturalnews.com)
  • There is limited information regarding Paclitaxel FDA-Labeled Indications and Dosage (Pediatric) in the drug label. (wikidoc.org)
  • The recommended regimen is paclitaxel 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks. (fresenius-kabi.com)
  • In both trials, the addition of sequentially administered paclitaxel to the AC regimen significantly improved disease-free survival at 5 years compared with AC alone. (nih.gov)
  • The weekly regimen included paclitaxel dosages that ranged from 60 to 90 mg/m2, infused over an hour. (cancernetwork.com)
  • We think that it may be of deserve to evaluate the efficacy of paclitaxel and irinotecan combination regimen in gastric cancer patients and it is necessary to conduct phase I study to find out the accurate MTD of this regimen after considering the UGT1A1 polymorphism of patients. (knowcancer.com)
  • Dexamethasone is given prior to paclitaxel infusion to mitigate some of the side effects. (wikipedia.org)
  • It appeared that with the 24-hour infusion of paclitaxel, a 30% increase in dose (135 mg/m 2 versus 175 mg/m 2 ) increased the C max by 87%, whereas the AUC (0-∞) remained proportional. (nih.gov)
  • The mean apparent volume of distribution at steady state, with the 24-hour infusion of paclitaxel, ranged from 227 to 688 L/m 2 indicating extensive extravascular distribution and/or tissue binding of paclitaxel. (nih.gov)
  • Paclitaxel protein-bound is given as an infusion into a vein. (rexhealth.com)
  • Paclitaxel also can cause a number of side effects, including infusion site reactions and neuropathy. (breastcancer.org)
  • In the phase I dose-findingstudy, 19 enrolled patients received bolus doxorubicin (50 mg/m²)and, after a 16-hour interval, a three-hour infusion of paclitaxel in escalatingdoses from 130 to 250 mg/m², increased by 30-mg/m² incrementsfor each dose-level group. (cancernetwork.com)
  • Typically, paclitaxel regimens entail a 3-hour infusion every 3 weeks. (cancernetwork.com)
  • tell your doctor and pharmacist if you are allergic to paclitaxel, docetaxel, any other medications, or human albumin, Ask your doctor or pharmacist if you do not know if a medication that you are allergic to contains human albumin. (medlineplus.gov)
  • A Case of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy without Exacerbation]. (springer.com)
  • Using albumin, a human protein, to mix the paclitaxel has proved to be a safe and less toxic way to deliver the drug. (healthcentral.com)
  • Paclitaxel albumin-stabilized nanoparticle formulation is also being studied in the treatment of other types of cancer . (cancer.gov)
  • For more information about paclitaxel that may apply to paclitaxel albumin-stabilized nanoparticle formulation, see the Drug Information Summary for Paclitaxel . (cancer.gov)
  • Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. (wikidoc.org)
  • The synthesis of related taxanes decinnamoyltaxinine E and taxabaccatin III has been reported The commercial semisynthesis (by Bristol-Myers Squibb) of paclitaxel starting from 10-deacetylbaccatin III (isolated from the European yew) is based on tail addition of the so-called Ojima lactam to its free hydroxyl group: Another commercial semisynthesis (by the company Natural Pharmaceuticals) relies on the isolation of a group of paclitaxel derivatives isolated from primary ornamental taxanes. (wikipedia.org)
  • The paclitaxel drug development process took over 40 years. (wikipedia.org)
  • Paclitaxel drug-eluting stents for femoropopliteal artery placement are also available. (wikipedia.org)
  • Patients who experience severe hypersensitivity reactions to paclitaxel should not be rechallenged with the drug. (nih.gov)
  • This has then been shown to be a prospective cancer therapy drug that can not only be conjugated to paclitaxel but also peptides, monoclonal antibodies, siRNA and many other biological materials. (wikipedia.org)
  • The drug is also called nanoparticle paclitaxel and protein-bound paclitaxel. (cancer.gov)
  • Paclitaxel drug-coated balloons and drug-eluting stents received some bad press in January after a meta-analysis showed an increased risk of death for patients treated with these devices in the femoral and/or popliteal arteries of the lower limbs. (medworm.com)
  • A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. (drugbank.ca)
  • A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now. (eurekalert.org)
  • The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries. (clinicaltrials.gov)
  • Paclitaxel (PCX) is the drug of first choice for ovarian cancer treatment, but it has low aqueous solubility, which reduces its bioavailability. (usp.br)
  • The combination of gemcitabine and paclitaxel is valuable because of the different mechanisms of action of each drug and their non-overlapping toxicities. (bioportfolio.com)
  • The investigators are also hoping to learn about the long term benefits and disease-free survival of participants who take the study drug T-DM1 in comparison to those participants to take the combination of trastuzumab and paclitaxel. (mayo.edu)
  • Paclitaxel is a frontline drug for the treatment of breast, ovarian and lung cancer. (canceractive.com)
  • The results were consistent and showed that where Paclitaxel was used a gene, Atf3, was over-expressed whereas in people who had not taken the drug, it was not over-expressed. (canceractive.com)
  • Paclitaxel is a drug that interferes with the ability of the vessel cells to divide and multiply, therefore reducing re-blockage and repeat procedures. (elliothospital.org)
  • For example, a Chinese study reported that the plant-based anti-cancer drug Paclitaxel can get a boost if you eat red grapes and other foods that are rich in the polyphenol called resveratrol . (naturalnews.com)
  • U.K. medtech regulators have recommended a ban on routine use of paclitaxel drug-coated balloons (DCBs) and drug-eluting stents in patients with intermittent leg cramps, but held back on recommending the same for patients with critical limb ischemia. (massdevice.com)
  • Drug information on Celtax (Paclitaxel) from Celon Laboratories Ltd. (medindia.net)
  • Our findings in the present study demonstrate a profound alteration of paclitaxel accumulation in erythrocytes caused by a trapping of the compound in CrEL micelles, thereby reducing the free drug fraction available for cellular partitioning. (aacrjournals.org)
  • It is proposed that the nonlinearity of paclitaxel plasma disposition in patients reported previously should be reevaluated prospectively by measuring the free drug fractions and whole blood:plasma concentration ratios. (aacrjournals.org)
  • Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell. (ecancer.org)
  • Among 201 patients with triple-negative disease, PFS was 6.4 months in the paclitaxel group, 7.4 months for nab-paclitaxel and 5.6 months for ixabepilone. (healio.com)
  • Median overall survival was 8.5 months for nab-paclitaxel/gemcitabine versus 6.7 months for gemcitabine alone. (eurekalert.org)
  • The chemical name for paclitaxel is 5ß, 20-Epoxy-1,2 a , 4,7ß, 10ß, 13 a -hexahydroxytax-11-en-9-one 4,10-diacetate 2- benzoate 13-ester with (2R, 3 S)- N -benzoyl-3-phenylisoserine. (egeneralmedical.com)
  • Evidence shows that nab-paclitaxel plus gemcitabine is more effective in increasing survival than gemcitabine monotherapy, but is less effective than FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan and oxaliplatin) and similarly effective to gemcitabine plus capecitabine (although the results were uncertain). (nice.org.uk)
  • Paclitaxel is a cancer medication that interferes with the growth and spread of cancer cells in the body. (cigna.com)
  • Paclitaxel may also be used for purposes not listed in this medication guide. (cigna.com)
  • You should not receive this medication if you are allergic to paclitaxel, or to other medications that contain an ingredient called Cremophor EL (polyoxyethylated castor oil). (cigna.com)
  • Paclitaxel is a natural product with antitumor activity. (nih.gov)
  • The present invention is directed to polymer-bound paclitaxel and polymer-bound paclitaxel derivatives endowed with antitumor -activity, to a method for their preparation and to pharmaceutical compositions containing them. (google.com)
  • In murine bladder tumor MBT-2 cells, paclitaxel has also been shown to activate a macrophage-mediated antitumor mechanism through a nitric oxide (NO)-dependent pathway ( 14 ). (aacrjournals.org)
  • What is the most important information I should know about paclitaxel protein-bound? (rexhealth.com)
  • Paclitaxel protein-bound is used to treat cancer of the breast, lung, or pancreas. (rexhealth.com)
  • Paclitaxel protein-bound is sometimes given with other cancer medicines. (rexhealth.com)
  • What should I discuss with my healthcare provider before receiving paclitaxel protein-bound? (rexhealth.com)
  • an allergic reaction to medicines like paclitaxel protein-bound (such as cabazitaxel or docetaxel). (rexhealth.com)
  • If you are a woman, do not use paclitaxel protein-bound if you are pregnant. (rexhealth.com)
  • Tell your doctor right away if a pregnancy occurs while either the mother or the father is using paclitaxel protein-bound. (rexhealth.com)
  • How is paclitaxel protein-bound given? (rexhealth.com)
  • Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when paclitaxel protein-bound is injected. (rexhealth.com)
  • Paclitaxel protein-bound can lower your blood cell counts. (rexhealth.com)
  • What should I avoid while using paclitaxel protein-bound? (rexhealth.com)
  • Paclitaxel protein-bound can be harmful if it gets in your eyes, mouth, or nose, or on your skin. (rexhealth.com)
  • Paclitaxel (protein bound) is generally given over 30 minutes. (chemocare.com)
  • Paclitaxel (protein bound) is an irritant. (chemocare.com)
  • The nurse or doctor who gives paclitaxel (protein bound) must be carefully trained. (chemocare.com)
  • If you experience pain or notice redness or swelling at the IV site while you are receiving paclitaxel (protein bound), alert your health care professional immediately. (chemocare.com)
  • The amount of paclitaxel (protein bound) that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition you have. (chemocare.com)
  • The following side effects are common (occurring in greater than 30%) for patients taking paclitaxel (protein bound). (chemocare.com)
  • Arthralgias and myalgias - pain in the joints and muscles (usually temporary occurring 2-3 days after paclitaxel (protein bound). (chemocare.com)
  • Before starting paclitaxel (protein bound) treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (chemocare.com)
  • locally delivered to the wall of the artery, a paclitaxel coating limits the growth of neointima (scar tissue) within stents. (wikipedia.org)
  • A second review, published just days earlier, also showed no excess mortality risk with paclitaxel-coated stents and balloons in 16,560 Medicare beneficiaries undergoing femoropopliteal artery revascularization. (medscape.com)
  • The controversy erupted in December 2018 when a meta-analysis of 28 randomized controlled trials (RCTs) reported a 68% relative risk increase in all-cause death with paclitaxel-coated balloons and stents beginning at 2 years that increased to 93% at 5 years. (medscape.com)
  • Mike Matson, a medtech analyst at Needham &Co., issued a report in February pointing to evidence and expert opinion that the benefits of using paclitaxel balloons and stents outweigh the risks. (medworm.com)
  • citation needed] A number of these side effects are associated with the excipient used, Cremophor EL, a polyoxyethylated castor oil, and allergies to cyclosporine, teniposide, and other drugs containing polyoxyethylated castor oil may increase the risk of adverse reactions to paclitaxel. (wikipedia.org)
  • Paclitaxel is among the most widely used anticancer drugs and is known to cause a dose-limiting peripheral neurotoxicity, the initiating mechanisms of which remain unknown. (jci.org)
  • Some drugs, like Paclitaxel, target the growth of cancer cells by stopping them from replicating. (blausen.com)
  • In this report, we have investigated the effects of BAX on the sensitivity of ovarian cancer cells to a variety of chemotherapeutic agents, including paclitaxel. (pnas.org)
  • Paclitaxel has antitumorigenic properties and has been used as a chemotherapeutic compound (Rowinsky et al. (stemcell.com)
  • The treatment with the chemotherapeutic paclitaxel (PTX) reduces the experimental and human GBM, however, their use is limited by side effects. (usp.br)
  • Paclitaxel, one of the most commonly prescribed chemotherapeutic agents, is active against a wide spectrum of human cancer. (aacrjournals.org)
  • This is a single arm phase 2 trial evaluating the efficacy and tolerability of intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer patients with peritoneal metastasis and/or cancer cells on peritoneal cytology. (clinicaltrials.gov)
  • TumorSelect ® Paclitaxel is a novel reformulation of paclitaxel that promises to improve both its efficacy and tolerability when compared with standard Cremophor ® as well as newer formulations. (prnewswire.com)
  • Cannabinoids work synergistically with paclitaxel in gastric cancer cell lines. (greenmedinfo.com)
  • 2003) The combination of paclitaxel and irinotecan in gastric cancer is evaluated in two studies until now as far as we know (K Kobayashi et al. (knowcancer.com)
  • Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts. (greenmedinfo.com)
  • Collectively, our findings reveal a pathway that explains the fundamental basis of paclitaxel-induced neurotoxicity, with potential implications for its therapeutic management. (jci.org)
  • Spencer, C.M. and Faulds, D. (1994) Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. (scirp.org)
  • Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. (greenmedinfo.com)
  • Palbociclib effectively halts the cell cycle before that point, and thus in principle can synchronize cancer cells in a way that makes them more vulnerable to a closely following dose of paclitaxel. (eurekalert.org)
  • The researchers ultimately settled on an optimal palbociclib dose of 75 mg per day, combined with a standard dose of paclitaxel. (eurekalert.org)
  • Both the dose of paclitaxel-L and the dose of paclitaxel-H halted the growth of liver cancer cells. (naturalnews.com)
  • This form may work better than other forms of paclitaxel and have fewer side effects . (cancer.gov)
  • It has been shown that cancer cell lines exposed to this hypoxic or serum-deprived condition will upregulate LRP1 expression, thus leading to an increased uptake of paclitaxel trevatide. (wikipedia.org)
  • Kinetic experiments revealed that this effect was caused by reduced erythrocyte uptake of paclitaxel by polyoxyethyleneglycerol triricinoleate, the major compound present in CrEL. (aacrjournals.org)
  • Cells with a defective G 1 checkpoint and with an increased percentage of G 2 -M fractions were found to have increased sensitivity to paclitaxel ( 6 - 8 ). (aacrjournals.org)
  • Before you begin treatment with paclitaxel, you and your doctor should talk about the good this medicine will do as well as the risks of using it. (mayoclinic.org)
  • The function of this transport system was inhibited by the tyrosine kinase inhibitor nilotinib through a noncompetitive mechanism, without compromising the anticancer properties of paclitaxel. (jci.org)
  • This notion is further supported with the observation that concentrations of paclitaxel required to inhibit cell growth by 50% correlate with total antioxidant capacity. (aacrjournals.org)
  • At present, the biochemical mechanisms responsible for the dose-dependent interaction of CrEL with the pharmacokinetics of paclitaxel remain unclear. (aacrjournals.org)
  • 3 In the present study, we have determined the in vitro and in vivo cellular distribution of paclitaxel in human blood in an effort to extend our insight into the role of CrEL in the pharmacokinetics of paclitaxel. (aacrjournals.org)